

SUBSTITUTED BENZIMIDAZOLES AND IMIDAZO-[4,5]-PYRIDINES

Field of the Invention

The present invention relates to substituted benzimidazole and imidazo-
5 [4,5]-pyridine compounds, compositions containing them, and methods of using them.

Background of the Invention

The maintenance of an intact genome is of crucial importance to every
10 organism. The individual cell in a multicellular eukaryotic organism possesses sophisticated and intricate mechanisms to properly respond to DNA damage. Such mechanisms repair damaged DNA or trigger programmed cell death (apoptosis). In response to DNA damage, checkpoint kinases are thought to be intimately involved in these processes. These kinases are activated by
15 upstream proteins, such as ATM (ataxia-telangiectasia mutated) and ATR (ataxia-telangiectasia mutated and rad3-related), and in turn trigger cell cycle arrest by inhibition of proteins such as Cdc25A or Cdc25C. The checkpoint kinases may also modulate the activity of other proteins that are thought to be involved in DNA repair and programmed cell death. Examples of such proteins
20 are BRCA1 and p53.

The checkpoint kinase Cds1 (in man also known as Chk2) is conserved from yeast to man. A human homolog of the *Schizosaccharomyces pombe* Cds1 gene has been described (Tominaga, K. et al. *J. Biol. Chem.* 1999, 274(44):31463–31467; Matsouka, S. et al. *Science* 1998, 282:1893–1897;
25 Blasina, A. et al. *Curr. Biol.* 1999, 9(1):1–10). Human Cds1 was rapidly activated by phosphorylation in response to DNA damage in both normal cells and in p53-deficient cancer cells. High levels of hCds1 were observed in p53-deficient cells. In human cells Cds1 has been implicated in the regulation by phosphorylation of proteins such as p53, BRCA1, Cdc25A, and Cdc25C (See:
30 Lee, J.-S. et al. *Nature* 2000, 404:201–204; Falck, J. et al. *Nature* 2001, 410:842–847; and Buscemi, G. et al. *Mol. Cell. Biol.* 2001, 21(15):5214–5221). As described below, inhibition of Cds1 offers two strategies for improving the effectiveness of DNA-damaging cancer treatments.

Cancer cells are often deficient in the mechanisms responsible for maintaining an intact genome. In particular, they have often lost proper p53 function, which generally correlates with the progression of a tumor to a more aggressive state, such as the progression from a preinvasive to invasive stage of colon cancer, or from a low grade to a high grade astrocytoma. Between 30% and 70% of all subtypes of tumors have a point mutation in one of the two p53 gene copies and have lost the other allele. P53-deficient cells are generally more resistant to radiation. It is thought that the lack of initiation of programmed cell death in cancer cells may render such cells less sensitive to DNA-damaging cancer treatments. The transcription factor p53 is of importance not only for the initiation of programmed cell death, but also in cell cycle arrest. Loss of p53 function may therefore leave cancer cells with limited protection against insult to the genome. Further disruption of DNA damage repair and cell cycle arrest by inhibition of kinases such as Cds1 could then render cancer cells unable to survive after DNA damage. Therefore inhibition of Cds1 could, by removing the remaining components of DNA damage repair, render the cancer cells more susceptible to treatments such as chemical DNA-damaging agents or ionizing radiation.

Normal cells, on the other hand, have an intact p53 system, and will often undergo apoptosis in response to DNA-damaging treatments at a much lower dose than that required to kill cancer cells. Therefore, in such situations, normal cells will be at a disadvantage compared to cancer cells, and cancer treatments often have to be discontinued due to serious side effects caused by loss of normal cells before the cancer has been eradicated. Inhibition of Cds1, which would prevent this kinase from phosphorylating and thereby stabilizing p53, could therefore protect normal cells from the effects of ionizing radiation or DNA-damaging chemotherapeutics while still allowing these agents to be effective against p53-deficient cancer cells. This would have the effect of increasing the therapeutic potential of these agents. This view is supported by studies of mice deficient in Cds1 (See: Hirao, A. et al. *Mol. Cell. Biol.* 2002, 22(18):6521–6532; Takai, H. et al. *EMBO J.* 2002, 21(19):5195–5205; WO 01/98465 A1 Chugai Seiyaku Kabushiki Kaisha, December 27, 2001). These animals showed increased resistance to the apoptosis caused by ionizing

radiation over their wild-type counterparts. For example, it was shown that these animals were protected from apoptosis of intestinal cells, hair follicle cells, cells of the CNS, and thymus cells relative to their wild-type counterparts when treated with ionizing radiation. Cds1 knockout animals also showed
5 increased survival when exposed to ionizing radiation. It is therefore logical to assume that chemical inhibitors of Cds1 would have therapeutic potential in the protection of patients from the deleterious side effects of radiation or DNA-damaging chemotherapeutics.

Additional examples of cell cycle checkpoint modulators in development
10 include UCN-01 (CAS 112953-11-4), UCN-02, KW-2401, NSC-638850 (Kyowa Hakko/National Cancer Institute) and SB-218078 (CAS 135897-06-2) (SmithKline Beecham).

Additional relevant publications include DE 0148431 (T 7570), WO
01/21771 A2, WO 02/072090 A1, WO 03/011219 A2, and White, A.W. et al. *J.*
15 *Med. Chem.* 2000, 43(22):4084–4097.

It is an object of the present invention to provide a Cds1-inhibiting adjuvant for use with ionizing radiation in the treatment of cancers.

It is another object of the present invention to provide a Cds1-inhibiting adjuvant for use with DNA-damaging chemotherapeutics in the treatment of
20 cancers.

It is still another object of the present invention to provide a Cds1-inhibiting adjuvant for use with ionizing radiation and/or DNA-damaging chemotherapeutics that promotes the death of cancer cells damaged by such radiation or chemotherapeutics.

It is yet another object of the present invention to provide a Cds1-inhibiting adjuvant for use with ionizing radiation and/or DNA-damaging chemotherapeutics that prevents apoptosis of healthy cells damaged by such
25 radiation or chemotherapeutics.

It is also an object of the present invention to provide a Cds1-inhibiting
30 adjuvant for use with ionizing radiation and/or DNA-damaging chemotherapeutics that both promotes in a patient the death of cancer cells and prevents the apoptosis of healthy cells damaged by such radiation or chemotherapeutics.

It is also another object of the present invention to provide a Cds1-inhibiting adjuvant for use with ionizing radiation and/or DNA-damaging chemotherapeutics in the treatment of p53-deficient cancer cells.

5 It is an additional object of the present invention to provide a Cds1-inhibiting adjuvant for use with ionizing radiation and/or DNA-damaging chemotherapeutics that both promotes in a patient the death of p53-deficient cancer cells and prevents the apoptosis of healthy cells damaged by such radiation or chemotherapeutics.

10 It is an object of the present invention to provide a method for the treatment of cancer in a patient comprising exposing the cancer to ionizing radiation and administering a Cds1-inhibiting adjuvant.

It is another object of the present invention to provide a method for the treatment of cancer in a patient comprising administering a DNA-damaging chemotherapeutic and a Cds1-inhibiting adjuvant.

15 It is still another object of the present invention to provide a method to promote in a patient the death of cancer cells damaged by exposure to ionizing radiation and/or by administration of a DNA-damaging chemotherapeutic comprising the step of administering a Cds1-inhibiting adjuvant in conjunction with such therapies.

20 It is yet another object of the present invention to provide a method to prevent in a patient the apoptosis of healthy cells damaged by exposure to ionizing radiation and/or by administration of a DNA-damaging chemotherapeutic comprising the step of administering a Cds1-inhibiting adjuvant in conjunction with such therapies.


25 It is also an object of the present invention to provide a method to both promote in a patient the death of cancer cells and prevent the apoptosis of healthy cells damaged by exposure to ionizing radiation and/or by administration of a DNA-damaging chemotherapeutic comprising the step of administering a Cds1-inhibiting adjuvant in conjunction with such therapies.

30 It is also another object of the present invention to provide a method for the treatment of p53-deficient cancer cells in a patient comprising exposing the cancer cells to ionizing radiation and/or administering a DNA-damaging chemotherapeutic and administering a Cds1-inhibiting adjuvant.

- It is an additional object of the present invention to provide a method to both promote in a patient the death of p53-deficient cancer cells and to prevent the apoptosis of healthy cells damaged by exposure to ionizing radiation and/or by administration of a DNA-damaging chemotherapeutic comprising the step of
- 5 administering a Cds1-inhibiting adjuvant in conjunction with such therapies.

Summary of the Invention

The present invention features compounds of formula (I):



- 10 wherein

W is $-\text{COOH}$, $-(\text{CO})\text{NH}_2$, or $-(\text{SO}_2)\text{NH}_2$;

Q is N or CH;

R_a and R_b are independently selected from $-\text{H}$ and halogen;

R_c is absent or is independently selected from the group consisting of $-\text{OH}$,


- 15 $-\text{CF}_3$, $-\text{C}_{1-4}\text{alkyl}$, $-\text{OC}_{1-4}\text{alkyl}$, $-\text{NO}_2$ and halo;

Z is selected from the group consisting of

a) $>\text{C}=\text{O}$, $>\text{C}=\text{CHR}_f$, $>\text{CR}_d\text{R}_d$, $>\text{CF}_2$, $>\text{CR}_d\text{OR}_e$, $>\text{C}(\text{OR}_d)\text{OR}_e$,


b) $>\text{C}(\text{R}_d)\text{NR}_d\text{R}_g$,

c) $-\text{SO}_2\text{NR}_d\text{C}(\text{R}_h)_2$,



20

where A is fused at the b or c faces, at a face of A which contains two carbon atoms, which is saturated or unsaturated,



25

where A is fused at the b or c faces, at a face of A which contains two carbon atoms, which is saturated or unsaturated,

d) $>\text{NC}_{1-4}\text{alkyl}$, where the alkyl is optionally substituted with a substituent selected from the group consisting of $-\text{NH}_2$, $-\text{NHC}_{1-4}\text{alkyl}$, $-\text{N}(\text{C}_{1-4}\text{alkyl})_2$, $-\text{CONH}_2$, $-\text{CONHC}_{1-4}\text{alkyl}$, $-\text{CON}(\text{C}_{1-4}\text{alkyl})_2$, $-\text{COOH}$, $-\text{COOC}_{1-4}\text{alkyl}$, $-\text{OH}$ and $-\text{OC}_{1-4}\text{alkyl}$;

- 5 R_d is independently selected from the group consisting of $-\text{H}$ and $-\text{C}_{1-4}\text{alkyl}$;
 R_e is independently selected from the group consisting of $-\text{H}$ and optionally mono- or di-substituted $-\text{C}_{1-4}\text{alkyl}$, where the substituent is independently selected from the group consisting of $-\text{NH}_2$, $-\text{NHC}_{1-4}\text{alkyl}$, $-\text{N}(\text{C}_{1-4}\text{alkyl})_2$, $-\text{CONH}_2$, $-\text{CONHC}_{1-4}\text{alkyl}$, $-\text{CON}(\text{C}_{1-4}\text{alkyl})_2$, $-\text{COOH}$, $-\text{COOC}_{1-4}\text{alkyl}$, $-\text{CN}$,
 10 $-\text{OH}$ and $-\text{OC}_{1-4}\text{alkyl}$;

alternatively, R_d and R_e may be taken together with their atoms of attachment to form a 5 to 8 membered heterocyclic ring, with the heterocyclic ring having 0 or 1 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having 0 or 1 additional heteroatom members separated from an atom of attachment by at least one carbon member and selected from
 15 O, S, $-\text{N}=\text{}$, $>\text{NH}$ or $>\text{NC}_{1-4}\text{alkyl}$ and having a maximum of two heteroatom ring members;

- R_f is independently selected from the group consisting of $-\text{H}$, $-\text{CONH}_2$, $-\text{CONHC}_{1-4}\text{alkyl}$, $-\text{CON}(\text{C}_{1-4}\text{alkyl})_2$, $-\text{COOH}$, $-\text{COOC}_{1-4}\text{alkyl}$ and optionally
 20 mono- or di-substituted $\text{C}_{1-4}\text{alkyl}$, where the substituent is independently selected from the group consisting of $-\text{NH}_2$, $-\text{NHC}_{1-4}\text{alkyl}$, $-\text{N}(\text{C}_{1-4}\text{alkyl})_2$, $-\text{CONH}_2$, $-\text{CONHC}_{1-4}\text{alkyl}$, $-\text{CON}(\text{C}_{1-4}\text{alkyl})_2$, $-\text{COOH}$, $-\text{COOC}_{1-4}\text{alkyl}$, $-\text{CN}$, $-\text{OH}$ and $-\text{OC}_{1-4}\text{alkyl}$;

- R_g is independently selected from the group consisting of $-\text{H}$ and optionally
 25 mono- or di-substituted $-\text{C}_{1-4}\text{alkyl}$, where the substituent is independently selected from the group consisting of $-\text{NH}_2$, $-\text{NHC}_{1-4}\text{alkyl}$, $-\text{N}(\text{C}_{1-4}\text{alkyl})_2$, $-\text{CONH}_2$, $-\text{CONHC}_{1-4}\text{alkyl}$, $-\text{CON}(\text{C}_{1-4}\text{alkyl})_2$, $-\text{COOH}$, $-\text{COOC}_{1-4}\text{alkyl}$, $-\text{CN}$, $-\text{OH}$ and $-\text{OC}_{1-4}\text{alkyl}$;

- alternatively, R_d and R_g may be taken together with their nitrogen of common
 30 attachment to form a 5 to 8 membered heterocyclic ring, with the heterocyclic ring having 0 or 1 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0 or 1 additional heteroatom

members separated from the atom of common attachment by at least one carbon member and selected from O, S, -N=, >NH or >NC₁₋₄alkyl;

R_h is independently selected from the group consisting of -H, and optionally mono- or di-substituted C₁₋₄alkyl, where the substituent is independently

5 selected from the group consisting of -NH₂, -NHC₁₋₄alkyl, -N(C₁₋₄alkyl)₂, -CN, -OH and -OC₁₋₄alkyl; or, alternatively, R_h is -CH₂CH₂- or -CH₂CH₂CH₂-, optionally substituted with R_i, which is bonded to a carbon of A adjacent to the carbon of Z attachment, forming a five- or six-membered carbocyclic ring;

10 R_i is independently selected from the group consisting of -H, -OH, -OC₁₋₄alkyl and optionally mono- or di-substituted C₁₋₄alkyl, where the substituent is independently selected from the group consisting of -NH₂, -NHC₁₋₄alkyl, -N(C₁₋₄alkyl)₂, -CONH₂, -CONHC₁₋₄alkyl, -CON(C₁₋₄alkyl)₂, -COOH, -COOC₁₋₄alkyl, -CN, -OH and -OC₁₋₄alkyl;

15 A is selected from the group consisting of:

a) phenyl, optionally mono-, di- or tri-substituted with R_p;

R_p is selected from the group consisting of -OH, -C₁₋₆alkyl, -OC₁₋₆alkyl, -C₃₋₆cycloalkyl, -OC₃₋₆cycloalkyl, -CN, -NO₂, -N(R_y)R_z (wherein R_y and R_z are independently selected from -H or -C₁₋₆alkyl, or may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >O, =N-, >NH or >N(C₁₋₄alkyl) and optionally having one or two unsaturated bonds in the ring), -(C=O)N(R_y)R_z,
 20 -(N-R_t)COR_t (wherein R_t is independently -H or -C₁₋₆alkyl), -(N-R_t)SO₂C₁₋₆alkyl, -(C=O)C₁₋₆alkyl, -(S(=O)_n)-C₁₋₆alkyl (wherein n is selected from 0, 1 or 2), -SO₂N(R_y)R_z, -SCF₃, halo, -CF₃, -OCF₃, -COOH, -C₁₋₆alkylCOOH, -COOC₁₋₆alkyl and -C₁₋₆alkylCOOC₁₋₆alkyl;

30 b) phenyl, attached at two adjacent ring members to a C₃₋₅alkyl moiety to form a fused 5 to 7 membered ring, said fused ring optionally having a second unsaturated bond, said fused ring optionally having one or two members replaced with =N-, >O, >NH or >N(C₁₋₄alkyl)

except that no such replacement is permitted where the fused ring is 5 membered and has a second unsaturated bond, and said fused ring optionally having one carbon member replaced with $>\text{C}=\text{O}$, the fused rings optionally mono-, di- or tri-substituted with R_p ;

5 c) a monocyclic aromatic hydrocarbon group having six ring carbon atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by N, and optionally mono- or di-substituted with R_p ;

10 d) a monocyclic aromatic hydrocarbon group having six ring carbon atoms, having a carbon atom which is the point of attachment, having zero, one or two carbon atoms replaced by N, and having attachment at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by $>\text{O}$,
15 $>\text{S}$, $>\text{NH}$ or $>\text{N}(\text{C}_{1-4}\text{alkyl})$ and which moiety has up to one additional carbon atom optionally replaced by N, the fused rings optionally mono-, di- or tri-substituted with R_p ;

e) a monocyclic aromatic hydrocarbon group having six ring carbon atoms, having a carbon atom which is the point of attachment,
20 having zero, one or two carbon atoms replaced by N, and having attachment at two adjacent carbon ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has zero, one or two carbon atoms replaced by N, the fused rings optionally mono-, di- or tri-substituted
25 with R_p ;

f) a monocyclic aromatic hydrocarbon group having five ring carbon atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by $>\text{O}$, $>\text{S}$, $>\text{NH}$ or $>\text{N}(\text{C}_{1-4}\text{alkyl})$,
30 having up to one additional carbon atom optionally replaced by N, and optionally mono- or di-substituted with R_p ;

g) a monocyclic aromatic hydrocarbon group having five ring carbon atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by $>\text{O}$, $>\text{S}$, $>\text{NH}$ or $>\text{N}(\text{C}_{1-4}\text{alkyl})$,

and having attachment at two adjacent carbon ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has zero, one or two carbon atoms replaced by N, the fused rings optionally mono-, di- or tri-substituted with R_p;

- h) a 4-7 membered aliphatic or heterocyclic ring said heterocyclic ring having a carbon atom which is the point of attachment, having 0 or 1 heteroatom members selected from O, S, -N=, >NH or >NR_p, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0, 1 or 2 substituents R_p,
- i) a benzo fused 4-7 membered aliphatic or heterocyclic ring said heterocyclic ring having a carbon atom which is the point of attachment, having 0 or 1 additional heteroatom members selected from O, S, -N=, >NH or >NR_p, having 0 or 1 additional unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halo substituents on the benzene ring only and having 0, 1 or 2 substituents R_p,

and enantiomers, diastereomers and pharmaceutically acceptable salts, esters or amides thereof.

In one aspect, the invention provides a method for treating a subject suffering from cancer, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a compound of formula (I). According to one aspect, the cancer is p-53 deficient.

In another aspect, the invention provides a method for treating a subject suffering from a p53-deficient tumor, said method comprising (a) administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a compound of formula (I) and (b) damaging the DNA of said subject, for example, by administration of a DNA-damaging treatment or agent, such as ionizing radiation or a chemical agent that causes DNA damage. In one aspect, the DNA damaging treatment is provided such that administration of the compound of formula (I) provides effective serum levels of the compound of formula (I) during the treatment and 12 hours to 5 days thereafter, for example, 1-2 days thereafter. In a further aspect, the method of

treatment further includes administration of one or more additional anti-cancer agents, to provide in total three or four (or more) agents, to be administered in an effective anti-cancer amount. Multiple or combination therapies may allow use of lower amounts of one or more of the individual agents, when compared with monotherapy, and thereby reducing the incidence or degree of adverse effects.

Examples of such DNA-damaging chemical agents are compounds that cause DNA strand breaks directly such as bleomycin. DNA damage may also be caused by alkylating agents such as hexamethylamine, busulfan, carboplatin, carmustine, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, mechlorethamine, melphalan, procarbazine, streptozocin or thiotepa, or combinations thereof. DNA damage may also be caused indirectly by topoisomerase inhibitors such as etoposide, irinotecan, teniposide, topotecan, and doxorubicin or by antimetabolites such as cladribine, cytarabine, floxuridine, 5-fluorouracil, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, pentostatin, thioguanine, and trietrexate. Enhancement of DNA damaging effects and improved therapeutic responses can be obtained by combining anticancer agents such as those exemplified above.

A third aspect of the invention provides the use, or the use for the manufacture of a medicament, of a disclosed compound for treating a tumor, in particular, a p53 deficient tumor, and more in particular, a tumor selected from lung, prostate, colon, brain, head and neck, and breast. Other tumors include tumors of the stomach, liver, and ovary. A p-53 deficient tumor is a tumor wherein the functions mediated by p53 are lacking or suppressed due to genetic mutations in the gene encoding p53 or through deficiencies or dysregulation of proteins that modulate p53 expression levels and function. Examples of such proteins are MDM2 and p14(ARF). A further aspect of the invention includes the treatment of a late-stage, e.g., stage 3 or stage 4, tumor.

The invention also features anti-cancer pharmaceutical compositions comprising as active ingredient an effective amount of a disclosed compound of formula (I), and a pharmaceutically acceptable carrier. The active ingredient can be formulated in any manner suitable for the particular tumor, including

aerosol, oral, injectable and topical formulations, and time-release formulations thereof.

Additional features and advantages of the invention will become apparent from the detailed description and examples below, and the appended
5 claims.

Detailed Description of the Invention

Preferably, W is $-(CO)NH_2$.

Preferably, Q is CH.

Preferably, R_a and R_b are -H, -Cl or -F.

10 More preferably, R_a is -H and R_b is -Cl or -F.

Most preferably, R_a and R_b are -H.

Preferably, R_c is absent or is selected from the group consisting of -OH, -CH₃, -CH₂CH₃, -F, -Cl, -Br, -I, -CF₃ and -OCH₃.

15 Most preferably, R_c is selected from the group consisting of -F, -Cl, -CH₃ and -OCH₃.

Most preferably, R_c is absent.

Preferably, R_d is selected from the group consisting of -H, -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH₂CH₂CH₃, -CH(CH₃)CH₂CH₃ and -C(CH₃)₃.

20 Most preferably, R_d is selected from the group consisting of -H, -CH₃ and -CH₂CH₃.


Preferably, R_e is selected from the group consisting of -H, -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH₂CH₂CH₃, -CH(CH₃)CH₂CH₃ and -C(CH₃)₃, where the alkyl members are optionally mono- or di-substituted.

25 Preferably the optional substituent is independently selected from the group consisting of -NH₂, -NHCH₃, -NHCH₂CH₃, -N(CH₃)₂, -N(CH₂CH₃)₂, -CONH₂, -CONHCH₃, -CONHCH₂CH₃, -CON(CH₃)₂, -CON(CH₂CH₃)₂, -COOH, -COOCH₃, -COOCH₂CH₃, -CN, -OH, -OCH₃, -OCH₂CH₃ and -OCH₂CH₂CH₃.

30 Most preferably, R_e is selected from the group consisting of -H, -CH₃ and -CH₂CH₃, where the alkyl members are optionally mono- or di-substituted. Most preferably the optional substituent is independently selected from the group consisting of -NH₂, -NHCH₃, -N(CH₃)₂, -CONH₂, -CONHCH₃, -CON(CH₃)₂, -COOH, -COOCH₃, -CN, -OH and -OCH₃.


Most preferably, R_e is -H or -CH₃.

Preferably, R_d and R_e taken together with their atoms of attachment form a heterocyclic ring selected from the group consisting of




said heterocyclic ring having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members which is a carbonyl, where Y is selected from O, S, -N=, >NH or >NC₁₋₄alkyl.

10 More preferably, R_d and R_e taken together with their atoms of attachment form a heterocyclic ring selected from the group consisting of




where Y is selected from O, >NH or >NC₁₋₄alkyl.

15 More preferably, R_d and R_e taken together with their atoms of attachment form a heterocyclic ring selected from the group consisting of



Most preferably, R_d and R_e taken together with their atoms of attachment form a heterocyclic ring selected from the group consisting of




- Preferably, R_f is selected from the group consisting of -H, -CONH₂, -CONHCH₃, -CONHCH₂CH₃, -CON(CH₃)₂, -CON(CH₂CH₃)₂, -COOH, -COOCH₃, -COOCH₂CH₃, -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH₂CH₂CH₃, -CH(CH₃)CH₂CH₃ and -C(CH₃)₃, where the alkyl members
- 5 are optionally mono- or di-substituted. Preferably, the optional substituents are independently selected from the group consisting of -NH₂, -NHCH₃, -NHCH₂CH₃, -N(CH₃)₂, -N(CH₂CH₃)₂, -CONH₂, -CONHCH₃, -CONHCH₂CH₃, -CON(CH₃)₂, -CON(CH₂CH₃)₂, -COOH, -COOCH₃, -COOCH₂CH₃, -CN, -OH, -OCH₃, -OCH₂CH₃ and -OCH₂CH₂CH₃.
- 10 More preferably, R_f is selected from the group consisting of -H, -CONH₂, -CONHCH₃, -CON(CH₃)₂, -COOH, -COOCH₃, -CH₃ and -CH₂CH₃, where the alkyl members are optionally mono- or di-substituted. Most preferably, the optional substituent is independently selected from the group consisting of -NH₂, -NHCH₃, -N(CH₃)₂, -CONH₂, -CONHCH₃, -CON(CH₃)₂, -COOH,
- 15 -COOCH₃, -CN, -OH and -OCH₃.

Most preferably, R_f is selected from the group consisting of -H and -CH₃.

- Preferably, R_g is selected from the group consisting of -H, -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH₂CH₂CH₃, -CH(CH₃)CH₂CH₃ and
- 20 -C(CH₃)₃, where the alkyl moieties are optionally mono- or di-substituted. Preferably, the optional substituent is independently selected from the group consisting of -NH₂, -NHCH₃, -NHCH₂CH₃, -N(CH₃)₂, -N(CH₂CH₃)₂, -CONH₂, -CONHCH₃, -CONHCH₂CH₃, -CON(CH₃)₂, -CON(CH₂CH₃)₂, -COOH, -COOCH₃, -COOCH₂CH₃, -CN, -OH, -OCH₃, -OCH₂CH₃ and -OCH₂CH₂CH₃.

- 25 Most preferably, R_g is selected from the group consisting of -H, -CH₃ and -CH₂CH₃ where the alkyl members are optionally mono- or di-substituted. Most preferably the optional substituent is independently selected from the group consisting of -NH₂, -NHCH₃, -N(CH₃)₂, -CONH₂, -CONHCH₃, -CON(CH₃)₂, -COOH, -COOCH₃, -CN, -OH and -OCH₃.


- 30 Preferably, R_d and R_g taken together with their nitrogen of attachment to form a heterocyclic ring are selected from the group consisting of



the heterocyclic ring having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members which is a carbonyl, where Y is selected from O, S, -N=, >NH or >NC₁₋₄alkyl.

5


More preferably, R_d and R_g taken together with their atoms of attachment to form a heterocyclic ring are selected from the group consisting of



where Y is selected from O, S, >NH or >NC₁₋₄alkyl.

10

Most preferably, R_d and R_g taken together with their atoms of attachment to form a heterocyclic ring are selected from the group consisting of



Preferably, R_h is selected from the group consisting of -H, -CONH₂, -CONHCH₃, -CONHCH₂CH₃, -CON(CH₃)₂, -CON(CH₂CH₃)₂, -COOH, -COOCH₃, -COOCH₂CH₃, -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH₂CH₂CH₃, -CH(CH₃)CH₂CH₃ and -C(CH₃)₃, where the alkyl members are optionally mono- or di-substituted. Preferably the optional substituent is independently selected from the group consisting of -NH₂, -NHCH₃,

15

-NHCH₂CH₃, -N(CH₃)₂, -N(CH₂CH₃)₂, -CONH₂, -CONHCH₃, -CONHCH₂CH₃, -CON(CH₃)₂, -CON(CH₂CH₃)₂, -COOH, -COOCH₃, -COOCH₂CH₃, -CN, -OH, -OCH₃, -OCH₂CH₃ and -OCH₂CH₂CH₃. Alternatively, R_h is -CH₂CH₂- or -CH₂CH₂CH₂-, which is bonded to a carbon of A adjacent to the carbon of Z attachment, forming a five- or six-membered carbocyclic ring.

20

25

More preferably, R_h is selected from the group consisting of -H, -CONH₂, -CONHCH₃, -CON(CH₃)₂, -COOH, -COOCH₃, -CH₃ and -CH₂CH₃, where the alkyl members are optionally mono- or di-substituted. Most preferably, the

optional substituent is independently selected from the group consisting of -NH₂, -NHCH₃, -N(CH₃)₂, -CONH₂, -CONHCH₃, -CON(CH₃)₂, -COOH, -COOCH₃, -CN, -OH and -OCH₃. Alternatively, R_h is -CH₂CH₂- or -CH₂CH₂CH₂-, which taken together with A forms indanyl or 1,2,3,4-tetrahydronaphthalenyl.


Most preferably, R_h is selected from the group consisting of -H, -CH₃ and -CH₂CH₃.

Preferably, R_i is selected from the group consisting of -H, -OH, -OCH₃, -OCH₂CH₃, -OCH₂CH₂CH₃, -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH₂CH₂CH₃, -CH(CH₃)CH₂CH₃ and -C(CH₃)₃, where the directly attached alkyl members are optionally mono- or di-substituted. Preferably the optional substituent is independently selected from the group consisting of -NH₂, -NHCH₃, -NHCH₂CH₃, -N(CH₃)₂, -N(CH₂CH₃)₂, -CONH₂, -CONHCH₃, -CONHCH₂CH₃, -CON(CH₃)₂, -CON(CH₂CH₃)₂, -COOH, -COOCH₃, -COOCH₂CH₃, -CN, -OH, -OCH₃, -OCH₂CH₃ and -OCH₂CH₂CH₃.

Most preferably, R_i is selected from the group consisting of -H, -OH, -OCH₃, -CH₃ and -CH₂CH₃, where the directly attached alkyl members are optionally mono- or di-substituted. Most preferably, the optional substituent is independently selected from the group consisting of -NH₂, -NHCH₃, -N(CH₃)₂, -CONH₂, -CONHCH₃, -CON(CH₃)₂, -COOH, -COOCH₃, -CN, -OH and -OCH₃.


Preferably Z is selected from the group consisting of

a) >C=O, >C=CH₂, >CH₂, >CHC₁₋₄alkyl, >CF₂, >CHOH, >CHOC₁₋₄alkyl,




b) >CHNR_dR_g;

c) -SO₂NR_dCH(R_h)-,



where A is fused at the c face, at a face of A which contains two carbon atoms, which is saturated or unsaturated,




where A is fused at the c face, at a face of A which contains two carbon atoms, which is saturated or unsaturated,


- d) $>\text{NCH}_3$, $>\text{NCH}_2\text{CH}_3$, $>\text{NCH}_2\text{CH}_2\text{CH}_3$, $>\text{NCH}(\text{CH}_3)_2$,
 5 $>\text{NCH}_2\text{CH}_2\text{CH}_2\text{CH}_3$, and $>\text{NCH}(\text{CH}_3)\text{CH}_2\text{CH}_3$, where the alkyl attached to
 $>\text{N}$ is optionally substituted with a substituent selected from the group
 consisting of $-\text{NH}_2$, $-\text{NHCH}_3$, $-\text{NHCH}_2\text{CH}_3$, $-\text{N}(\text{CH}_3)_2$, $-\text{N}(\text{CH}_2\text{CH}_3)_2$, $-\text{CONH}_2$,
 $-\text{CONHCH}_3$, $-\text{CONHCH}_2\text{CH}_3$, $-\text{CON}(\text{CH}_3)_2$, $-\text{CON}(\text{CH}_2\text{CH}_3)_2$, $-\text{COOH}$,
 $-\text{COOCH}_3$, $-\text{COOCH}_2\text{CH}_3$, $-\text{OH}$, $-\text{OCH}_3$, $-\text{OCH}_2\text{CH}_3$ and $-\text{OCH}_2\text{CH}_2\text{CH}_3$.

10 Most preferably, Z is selected from the group consisting of

- a) $>\text{C}=\text{O}$, $>\text{C}=\text{CHR}_f$, $>\text{CHR}_d$, $>\text{CF}_2$, $>\text{CHOR}_e$,




- b) $>\text{CHNHR}_g$, $>\text{CHNCH}_3\text{R}_g$,



15


where Y is selected from O, S, $-\text{N}=\text{}$, $>\text{NH}$ or $>\text{NC}_{1-4}\text{alkyl}$;

- c) $-\text{SO}_2\text{NHCH}_2-$, $-\text{SO}_2\text{NCH}_2\text{CH}_2-$,



where A is fused at the c face, at a face of A which contains two carbon atoms, which is saturated or unsaturated,

20



where A is fused at the c face, at a face of A which contains two carbon atoms, which is saturated or unsaturated,

- d) $>\text{NCH}_3$, $>\text{NCH}_2\text{CH}_3$, $>\text{NCH}_2\text{CH}_2\text{CH}_3$, $>\text{NCH}(\text{CH}_3)_2$, where the alkyl attached to $>\text{N}$ is optionally substituted with a substituent selected from the group consisting of $-\text{NH}_2$, $-\text{NHCH}_3$, $-\text{NHCH}_2\text{CH}_3$, $-\text{N}(\text{CH}_3)_2$, $-\text{N}(\text{CH}_2\text{CH}_3)_2$, $-\text{CONH}_2$, $-\text{CONHCH}_3$, $-\text{CONHCH}_2\text{CH}_3$, $-\text{CON}(\text{CH}_3)_2$, $-\text{CON}(\text{CH}_2\text{CH}_3)_2$, $-\text{COOH}$, $-\text{COOCH}_3$, $-\text{COOCH}_2\text{CH}_3$, $-\text{OH}$, $-\text{OCH}_3$, $-\text{OCH}_2\text{CH}_3$ and $-\text{OCH}_2\text{CH}_2\text{CH}_3$.

Preferably, A, optionally substituted with R_p , is selected from the group consisting of:

- a) phenyl,
- 10 b) tetralin-5, 6, 7 or 8-yl, chroman-5, 6, 7 or 8-yl, benzo-1,2-pyran-5, 6, 7 or 8-yl, benzo-2,3-pyran-5, 6, 7 or 8-yl, coumarin-5, 6, 7 or 8-yl, isocoumarin-5, 6, 7 or 8-yl, benzo-1,3,2-benzoxazin-5, 6, 7 or 8-yl, benzo-1,4-dioxan-5, 6, 7 or 8-yl, 1,2,3,4-tetrahydroquinolin-5, 6, 7 or 8-yl, 1,2,3,4-tetrahydroquinoxalin-5, 6, 7 or 8-yl, thiochroman-5, 6, 7 or 8-yl,
- 15 2,3-dihydrobenzo[1,4]dithiin-5, 6, 7 or 8-yl, 1,2,3,4-tetrahydroisoquinolin-5, 6, 7 or 8-yl, indene-4, 5, 6, or 7-yl, 1, 2, 3, 4-tetrahydronaphth-5, 6, 7, or 8-yl, 1,2-dihydroisoindolo-4, 5, 6, or 7-yl, 2, 3-dihydroindene-4, 5, 6, or 7-yl, benzo-1,3-dioxol-4, 5, 6 or 7-yl, 2,3-dihydroindol-4, 5, 6 or 7-yl, 2,3-dihydrobenzofuran-4, 5, 6 or 7-yl, 2,3-dihydrobenzothiophen-4, 5, 6 or 7-yl, 2,3-dihydrobenzimidazol-4, 5, 6 or 7-yl,
- 20 c) pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl,
- d) benzoxazol-4, 5, 6 or 7-yl, benzothiophen-4, 5, 6 or 7-yl, benzofuran-4, 5, 6 or 7-yl, indol-4, 5, 6 or 7-yl, benzthiazol-4, 5, 6 or 7-yl, benzimidazo-4, 5, 6 or 7-yl, indazol-4, 5, 6 or 7-yl, 1H-pyrrolo[2,3-b]pyridin-4, 5 or 6-yl,
- 25 1H-pyrrolo[3,2-c]pyridin-4, 6 or 7-yl, 1H-pyrrolo[2,3-c]pyridin-4, 5 or 7-yl, 1H-pyrrolo[3,2-b]pyridin-5, 6 or 7-yl, purin-2-yl,
- e) isoquinolin-5, 6, 7 or 8-yl, quinolin-5, 6, 7 or 8-yl, quinoxalin-5, 6, 7 or 8-yl, quinazolin-5, 6, 7 or 8-yl, naphthyridinyl,
- f) furanyl, oxazolyl, isoxazolyl, thiophenyl, thiazolyl, isothiazolyl, pyrrolyl,
- 30 imidazolyl, pyrazolyl, and
- g) benzoxazol-2-yl, benzothiophen-2 or 3-yl, benzofuran-2 or 3-yl, indol-2 or 3-yl, benzthiazol-2-yl, benzimidazo-2-yl, indazol-3-yl, 1H-pyrrolo[2,3-

b]pyridin-2 or 3-yl, 1H-pyrrolo[3,2-c]pyridin-2 or 3-yl, 1H-pyrrolo[2,3-c]pyridin-2 or 3-yl, 1H-pyrrolo[3,2-b]pyridin-2 or 3-yl, purin-8-yl.

More preferably, A, optionally substituted with R_p , is selected from the group consisting of:

- 5 a) phenyl,
- b) coumarin-5, 6, 7 or 8-yl, benzo-1,4-dioxan-5, 6, 7 or 8-yl, 1,2,3,4-tetrahydroquinolin-5, 6, 7 or 8-yl, 1,2,3,4-tetrahydroisoquinolin-5, 6, 7 or 8-yl, indene-4, 5, 6, or 7-yl, 1,2,3,4-tetrahydronaphth-5, 6, 7, or 8 yl, 1,2-dihydroisoindolo-4, 5, 6, or 7-yl, 2,3-dihydroindene-4, 5, 6, or 7-yl, benzo-10 1,3-dioxol-4, 5, 6 or 7-yl, 2,3-dihydroindol-4, 5, 6 or 7-yl, 2,3-dihydrobenzofuran-4, 5, 6 or 7-yl, 2,3-dihydrobenzothiophen-4, 5, 6 or 7-yl,
- c) pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl,
- d) benzothiophen-4, 5, 6 or 7-yl, benzofuran-4, 5, 6 or 7-yl, indol-4, 5, 6 or 15 7-yl,
- e) isoquinolin-5, 6, 7 or 8-yl, quinolin-5, 6, 7 or 8-yl,
- f) furanyl, oxazolyl, isoxazolyl, thiophenyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, and
- g) benzoxazol-2-yl, benzothiophen-2 or 3-yl, benzofuran-2 or 3-yl, indol-20 or 3-yl.

Most preferably A, optionally substituted with R_p , is selected from the group consisting of: phenyl, benzo-1,4-dioxan-5, 6, 7 or 8-yl, indene-4, 5, 6, or 7-yl, 1, 2, 3, 4-tetrahydronaphth-5, 6, 7, or 8 yl, 2, 3-dihydroindene-4, 5, 6, or 7-yl, benzo-1,3-dioxol-4, 5, 6 or 7-yl, 2,3-dihydroindol-4, 5, 6 or 7-yl, 25 2,3-dihydrobenzofuran-4, 5, 6 or 7-yl, 2,3-dihydrobenzothiophen-4, 5, 6 or 7-yl, pyridinyl, benzothiophen-4, 5, 6 or 7-yl, benzofuran-4, 5, 6 or 7-yl, indol-4, 5, 6 or 7-yl, furanyl, thiophenyl, pyrrolyl, pyrazolyl, and benzothiophen-2 or 3-yl, benzofuran-2 or 3-yl and indol-2 or 3-yl.

A specific A, including the R_p substituent, is selected from the group 30 consisting of pyridyl, phenyl, naphthyl, quinolinyl, cyclohexyl, 4-chloro phenyl, 4-methyl-3-chloro phenyl, 4-chloro-3-trifluoromethyl phenyl, 3,4-dichloro phenyl, 3-chloro-4-fluoro phenyl, 2-fluoro-5-trifluoromethyl, 4-chloro-3-fluoro phenyl, 3,4-dimethyl phenyl, 2-naphthyl, 4-trifluoromethyl phenyl, 4-bromo

phenyl, 4-fluoro-3-methyl phenyl, 3-chloro phenyl, tetrahydronaphthyl, 5-chloro-2-methyl phenyl, 3-trifluoromethyl phenyl, 4-methoxy phenyl, 4-methyl phenyl, 3,4-dimethyl phenyl, 2-fluoro-3-trifluoromethyl phenyl, 2-chloro-4-methyl phenyl, 4-ethyl phenyl, 4-fluoro phenyl, 3,4-dimethoxy phenyl, 3,4-dimethoxy-5-bromo phenyl, 3-(dimethylamino) phenyl, 4-nitro phenyl, 4-cyano phenyl, 2-methoxy-4-methyl phenyl, 4-trifluoromethoxy phenyl, 2-chloro phenyl, 4-morpholino phenyl, 3-chloro phenyl, 2,3-dichloro phenyl, benzo[1,3]dioxolyl, benzo[1,4]dioxinyl, 4-amino phenyl, 4-hydroxy phenyl, 4-bromo-3-hydroxy phenyl, 4-chloro-2-hydroxy phenyl, 4-chloro-3-hydroxy phenyl, 2,4-dichloro phenyl, 4-bromo-3-methoxy phenyl and 4-iodo phenyl.

A specific A, including the R_p substituent, is selected from the group consisting of phenyl, 4-chlorophenyl, 4-methylphenyl, 4-methoxyphenyl, 2-naphthalenyl, 4-chloro-3-trifluoromethylphenyl, 3-bromo-4,5-dimethoxyphenyl, 3,4-dichlorophenyl, 3,4-dimethylphenyl, 4-ethylphenyl, benzo[1,3]dioxolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 3-quinolinyl, 4-pyridyl, cyclohexyl, 4-tetrahydropyranyl, 2-thiophenyl, 6-chloro-benzo[1,3]dioxolyl, 2-chlorophenyl, 2,4-dichlorophenyl, 2-methoxyphenyl, 2-methylphenyl, 3-methylphenyl, and 2-furanyl.

Preferably R_p is selected from the group consisting of -OH, -CH₃, -CH₂CH₃, -OCH₃, -OCH₂CH₃, -OCH(CH₃)₂, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -Ocyclopentyl, -Ocyclohexyl, -CN, -NO₂, -C(O)NH₂, -C(O)N(CH₃)₂, -C(O)NH(CH₃), -NHCOCH₃, -NCH₃COCH₃, -NHSO₂CH₃, -NCH₃SO₂CH₃, -C(O)CH₃, -SOCH₃, -SO₂CH₃, -SO₂NH₂, -SO₂NHCH₃, -SO₂N(CH₃)₂, -SCF₃, -F, -Cl, -Br, -I, -CF₃, -OCF₃, -COOH, -COOCH₃, -COOCH₂CH₃, -NH₂, -NHCH₃, -N(CH₃)₂, -N(CH₂CH₃)₂, -NCH₃(CH(CH₃)₂), imidazolidin-1-yl, 2-imidazolin-1-yl, pyrazolidin-1-yl, piperidin-1-yl, 2- or 3-pyrrolin-1-yl, 2-pyrazolinyl, morpholin-4-yl, thiomorpholin-4-yl, piperazin-1-yl, pyrrolidin-1-yl, homopiperidin-1-yl.

Most preferably R_p is selected from the group consisting of -H, -OH, -OCH₃, -OCF₃, -CH₃, -CH₂CH₃, -CF₃, -F, -Cl, -Br, -I, -NH₂, -N(CH₃)₂, morpholin-4-yl, -NO₂, -CN, -C(O)NH₂, -COOH, -NHSO₂CH₃, -SO₂NH₂.

The invention features pharmaceutically active, substituted benzimidazole compounds as disclosed in the Summary section above.

A. Terms

The following terms are defined below and by their usage throughout this disclosure.

5 “Alkyl” includes optionally substituted straight chain and branched hydrocarbons with at least one hydrogen removed to form a radical group. Alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, 1-methylpropyl, pentyl, isopentyl, sec-pentyl, hexyl, heptyl, octyl, and so on. Alkyl includes cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, and
10 cyclohexyl.

 “Alkenyl” includes optionally substituted straight chain and branched hydrocarbon radicals as above with at least one carbon-carbon double bond (sp^2). Alkenyls include ethenyl (or vinyl), prop-1-enyl, prop-2-enyl (or allyl), isopropenyl (or 1-methylvinyl), but-1-enyl, but-2-enyl, butadienyls, pentenyls,
15 hexa-2,4-dienyl, and so on. Hydrocarbon radicals having a mixture of double bonds and triple bonds, such as 2-penten-4-ynyl, are grouped as alkynyls herein. Alkenyl includes cycloalkenyl. *Cis* and *trans* or (E) and (Z) forms are included within the invention.

 “Alkynyl” includes optionally substituted straight chain and branched
20 hydrocarbon radicals as above with at least one carbon-carbon triple bond (sp). Alkynyls include ethynyl, propynyls, butynyls, and pentynyls. Hydrocarbon radicals having a mixture of double bonds and triple bonds, such as 2-penten-4-ynyl, are grouped as alkynyls herein. Alkynyl does not include cycloalkynyl.

 “Alkoxy” includes an optionally substituted straight chain or branched
25 alkyl group with a terminal oxygen linking the alkyl group to the rest of the molecule. Alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy and so on. “Aminoalkyl”, “thioalkyl”, and “sulfonylalkyl” are analogous to alkoxy, replacing the terminal oxygen atom of alkoxy with, respectively, NH (or NR), S, and SO₂. Heteroalkyl includes alkoxy, aminoalkyl,
30 thioalkyl, and so on.

 “Aryl” includes phenyl, naphthyl, biphenyl, tetrahydronaphthyl, and so on, any of which may be optionally substituted. Aryl also includes arylalkyl groups such as benzyl, phenethyl, and phenylpropyl. Aryl includes a ring

system containing an optionally substituted 6-membered carbocyclic aromatic ring, said system may be bicyclic, bridge, and/or fused. The system may include rings that are aromatic, or partially or completely saturated. Examples of ring systems include indenyl, pentalenyl, 1-4-dihydronaphthyl, indanyl, benzimidazolyl, benzothiophenyl, indolyl, benzofuranyl, isoquinolinyl, and so on.

"Heterocyclyl" includes optionally substituted aromatic and nonaromatic rings having carbon atoms and at least one heteroatom (O, S, N) or heteroatom moiety (SO₂, CO, CONH, COO) in the ring. Unless otherwise indicated, a heterocyclic radical may have a valence connecting it to the rest of the molecule through a carbon atom, such as 3-furyl or 2-imidazolyl, or through a heteroatom, such as N-piperidyl or 1-pyrazolyl. Preferably a monocyclic heterocyclyl has between 4 and 7 ring atoms, or between 5 and 6 ring atoms; there may be between 1 and 5 heteroatoms or heteroatom moieties in the ring, and preferably between 1 and 3. A heterocyclyl may be saturated, unsaturated, aromatic (e.g., heteroaryl), nonaromatic, or fused.

Heterocyclyl also includes fused, e.g., bicyclic, rings, such as those optionally condensed with an optionally substituted carbocyclic or heterocyclic five- or six-membered aromatic ring. For example, "heteroaryl" includes an optionally substituted six-membered heteroaromatic ring containing 1, 2 or 3 nitrogen atoms condensed with an optionally substituted five- or six-membered carbocyclic or heterocyclic aromatic ring. Said heterocyclic five- or six-membered aromatic ring condensed with the said five- or six-membered aromatic ring may contain 1, 2 or 3 nitrogen atoms where it is a six-membered ring, or 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulfur where it is a five-membered ring.

Examples of heterocyclyls include thiazolyl, furyl, pyranlyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazoliny, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl. For example, preferred heterocyclyls or heterocyclic radicals include morpholinyl,

piperaziny, pyrrolidinyl, pyridyl, cyclohexylimino, cycloheptylimino, and more preferably, piperidyl.

Examples illustrating heteroaryl are thienyl, furanyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, benzothienyl, benzofuranyl, benzimidazolyl, benzoxazolyl, 5 benzothiazolyl.

"Acyl" refers to a carbonyl moiety attached to either a hydrogen atom (i.e., a formyl group) or to an optionally substituted alkyl or alkenyl chain, or heterocyclyl.

10 "Halo" or "halogen" includes fluoro, chloro, bromo, and iodo, and preferably chloro or bromo as a substituent.

"Alkanediyl" or "alkylene" represents straight or branched chain optionally substituted bivalent alkane radicals such as, for example, methylene, ethylene, propylene, butylene, pentylene or hexylene.

15 "Alkenediyl" represents, analogous to the above, straight or branched chain optionally substituted bivalent alkene radicals such as, for example, propenylene, butenylene, pentenylene or hexenylene. In such radicals, the carbon atom linking a nitrogen preferably should not be unsaturated.

"Aroyl" refers to a carbonyl moiety attached to an optionally substituted aryl or heteroaryl group, wherein aryl and heteroaryl have the definitions 20 provided above. In particular, benzoyl is phenylcarbonyl.

As defined herein, two radicals, together with the atom(s) to which they are attached may form an optionally substituted 4- to 7-, 5- to 7-, or a 5- to 6-membered ring carbocyclic or heterocyclic ring, which ring may be saturated, unsaturated or aromatic. Said rings may be as defined above in the Summary 25 of the Invention section. Particular examples of such rings are as follows in the next section.

30 "Pharmaceutically acceptable salts, esters, and amides" include carboxylate salts (e.g., C₁₋₈ alkyl, C₃₋₈ cycloalkyl, aryl, C₂₋₁₀ heteroaryl, or C₂₋₁₀ non-aromatic heterocyclic) amino acid addition salts, esters, and amides that are within a reasonable benefit/risk ratio, pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate,

palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulfonate. These may include alkali metal and alkali earth cations such as sodium, potassium, calcium, and magnesium, as well as non-toxic ammonium, quaternary ammonium, and amine cations such as tetramethyl ammonium, methylamine, trimethylamine, and ethylamine. See example, S.M. Berge, et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977, 66:1-19, which is incorporated herein by reference.

Representative pharmaceutically acceptable amides of the invention include those derived from ammonia, primary C₁₋₆ alkyl amines and secondary di (C₁₋₆ alkyl) amines. Secondary amines include 5- or 6-membered heterocyclic or heteroaromatic ring moieties containing at least one nitrogen atom and optionally between 1 and 2 additional heteroatoms. Preferred amides are derived from ammonia, C₁₋₃ alkyl primary amines, and di (C₁₋₂ alkyl)amines.

Representative pharmaceutically acceptable esters of the invention include C₁₋₇ alkyl, C₅₋₇ cycloalkyl, phenyl, and phenyl(C₁₋₆)alkyl esters. Preferred esters include methyl esters.

"Patient" or "subject" includes mammals such as humans and animals (dogs, cats, horses, rats, rabbits, mice, non-human primates) in need of observation, experiment, treatment or prevention in connection with the relevant disease or condition. Preferably, the patient or subject is a human.

"Composition" includes a product comprising the specified ingredients in the specified amounts as well as any product that results directly or indirectly from combinations of the specified ingredients in the specified amounts.

"Therapeutically effective amount" or "effective amount" means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the condition or disorder being treated.

Concerning the various radicals in this disclosure and in the claims, three general remarks are made. The first remark concerns valency. As with all hydrocarbon radicals, whether saturated, unsaturated or aromatic, and whether or not cyclic, straight chain, or branched, and also similarly with all

heterocyclic radicals, each radical includes substituted radicals of that type and monovalent, bivalent, and multivalent radicals as indicated by the context of the claims. The context will indicate that the substituent is an alkylene or hydrocarbon radical with at least two hydrogen atoms removed (bivalent) or
 5 more hydrogen atoms removed (multivalent). An example of a bivalent radical linking two parts of the molecule is Z in formula (I), which links X and A.

Second, radicals or structure fragments as defined herein are understood to include substituted radicals or structure fragments. Hydrocarbyls include monovalent radicals containing carbon and hydrogen such as alkyl,
 10 alkenyl, alkynyl, cycloalkyl, and cycloalkenyl (whether aromatic or unsaturated), as well as corresponding divalent radicals such as alkylene, alkenylene, phenylene, and so on. Heterocarbyls include monovalent and divalent radicals containing carbon, hydrogen, and at least one heteroatom. Examples of monovalent heterocarbyls include acyl, acyloxy, alkoxyacyl, heterocyclyl,
 15 heteroaryl, aroyl, benzoyl, dialkylamino, hydroxyalkyl, and so on. Using "alkyl" as an example, "alkyl" should be understood to include substituted alkyl having one or more substitutions, such as between 1 and 5, 1 and 3, or 2 and 4 substituents. The substituents may be the same (dihydroxy, dimethyl), similar (chlorofluoro), or different (chlorobenzyl- or aminomethyl-substituted).
 20 Examples of substituted alkyl include haloalkyl (such as fluoromethyl, chloromethyl, difluoromethyl, perchloromethyl, 2-bromoethyl, perfluoromethyl, and 3-iodocyclopentyl), hydroxyalkyl (such as hydroxymethyl, hydroxyethyl, 2-hydroxypropyl, aminoalkyl (such as aminomethyl, 2-aminoethyl, 3-aminopropyl, and 2-aminopropyl), nitroalkyl, alkylalkyl, and so on. A di(C₁₋₆ alkyl)amino
 25 group includes independently selected alkyl groups, to form, for example, methylpropylamino and isopropylmethylamino, in addition dialkylamino groups having two of the same alkyl group such as dimethyl amino or diethylamino.

Third, only stable compounds are intended. For example, where there is an NR'R'' group, and R can be an alkenyl group, the double bond is at least
 30 one carbon removed from the nitrogen to avoid enamine formation. Similarly, where a dashed line is an optional sp² bond, if it is absent, the appropriate hydrogen atom(s) is (are) included.

Compounds of the invention are further described in the next section.

B. Compounds

The invention features the treatment, or inhibition of onset or progression, of cancer using one or more Cds1 inhibitors as described in the Summary section.

5

Preferred compounds are made according to the synthetic methods outlined in Schemes 1–9, have demonstrated Cds1 inhibitory activity, and are selected from the group consisting of:

EX	Compound Name
1	2-[4-(2-Phenyl-[1,3]dioxolan-2-yl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
2	2-{4-[2-(4-Chloro-phenyl)-[1,3]dioxolan-2-yl]-phenyl}-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
3	2-(4-Benzoyl-phenyl)-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
4	2-[4-(4-Chloro-benzoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
5	2-[4-(4-Methyl-benzoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
6	2-[4-(4-Methoxy-benzoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
7	2-[4-(Naphthalene-2-carbonyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
8	2-[4-(4-Chloro-3-trifluoromethyl-benzoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
9	2-[4-(3-Bromo-4,5-dimethoxy-benzoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
10	2-[4-(3,4-Dichloro-benzoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
11	2-[4-(3,4-Dimethyl-benzoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
12	2-[4-(4-Ethyl-benzoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;

13	2-[4-(Benzo[1,3]dioxole-5-carbonyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
14	2-[4-(2,3-Dihydro-benzo[1,4]dioxine-6-carbonyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
15	2-[4-(Quinoline-3-carbonyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
16	2-[4-(Pyridine-4-carbonyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
17	2-(4-Cyclohexanecarbonyl-phenyl)-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
18	2-[4-(4-Chloro-benzoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-sulfonic acid amide;
19	2-[4-(Hydroxy-phenyl-methyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
20	2-{4-[(4-Chloro-phenyl)-hydroxy-methyl]-phenyl}-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
21	2-[4-(Hydroxy-p-tolyl-methyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
22	2-{4-[Hydroxy-(4-methoxy-phenyl)-methyl]-phenyl}-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
23	2-[4-(Hydroxy-naphthalen-2-yl-methyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
24	2-{4-[(4-Chloro-3-trifluoromethyl-phenyl)-hydroxy-methyl]-phenyl}-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
25	2-{4-[(3-Bromo-4,5-dimethoxy-phenyl)-hydroxy-methyl]-phenyl}-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
26	2-{4-[(3,4-Dichloro-phenyl)-hydroxy-methyl]-phenyl}-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
27	2-{4-[(3,4-Dimethyl-phenyl)-hydroxy-methyl]-phenyl}-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
28	2-{4-[(4-Ethyl-phenyl)-hydroxy-methyl]-phenyl}-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;

29	2-[4-(Benzo[1,3]dioxol-5-yl-hydroxy-methyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
30	2-{4-[(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-hydroxy-methyl]-phenyl}-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
31	2-[4-(Hydroxy-quinolin-3-yl-methyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
32	2-[4-(Hydroxy-pyridin-4-yl-methyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
33	2-[4-(Cyclohexyl-hydroxy-methyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
34	2-[4-(Methoxy-phenyl-methyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
35	2-[4-(4-Chloro-benzyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
36	2-(4-Naphthalen-2-ylmethyl-phenyl)-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
37	2-[4-(3,4-Dimethyl-benzyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
38	2-[4-(4-Ethyl-benzyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
39	2-[4-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
40	2-(4-Cyclohexylmethyl-phenyl)-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
41	2-{4-[1-(4-Chloro-phenyl)-vinyl]-phenyl}-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
42	2-{4-[1-(4-Chloro-phenyl)-ethyl]-phenyl}-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
43	2-{4-[(4-Chloro-phenyl)-piperazin-1-yl-methyl]-phenyl}-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
44	2-(4-{(4-Chloro-phenyl)-[methyl-(2-methylamino-ethyl)-amino]-methyl}-phenyl)-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;

45	2-[4-(Methyl-phenyl-amino)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
46	2-(4-Benzylsulfamoyl-phenyl)-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
47	2-[4-(4-Methyl-benzylsulfamoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
48	2-[4-(4-Methoxy-benzylsulfamoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
49	2-[4-(4-Chloro-benzylsulfamoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
50	2-[4-(3,4-Dichloro-benzylsulfamoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
51	2-[4-(Benzyl-methyl-sulfamoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
52	2-[4-(Tetrahydro-pyran-4-carbonyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
53	2-[4-(Thiophene-2-carbonyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
54	2-[4-(6-Chloro-benzo[1,3]dioxole-5-carbonyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
55	2-[4-(2-Chloro-benzoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
56	2-[4-(2,4-Dichloro-benzoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
57	2-[4-(2-Methoxy-benzoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
58	2-[4-(2-Methyl-benzoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
59	2-[4-[Hydroxy-(tetrahydro-pyran-4-yl)-methyl]-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
60	2-[4-(Hydroxy-thiophen-2-yl-methyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;

61	2-{4-[(6-Chloro-benzo[1,3]dioxol-5-yl)-hydroxy-methyl]-phenyl}-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
62	2-{4-[(2-Chloro-phenyl)-hydroxy-methyl]-phenyl}-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
63	2-{4-[(2,4-Dichloro-phenyl)-hydroxy-methyl]-phenyl}-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
64	2-{4-[Hydroxy-(2-methoxy-phenyl)-methyl]-phenyl}-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
65	2-[4-(Hydroxy- <i>o</i> -tolyl-methyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
66	2-[4-(6-Chloro-benzo[1,3]dioxol-5-ylmethyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
67	2-[4-(2-Methoxy-benzyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
68	2-[4-(2-Methyl-benzyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
69	2-[4-(2-Methyl-benzylsulfamoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
70	2-[4-(3-Methyl-benzylsulfamoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
71	2-[4-(1,3-Dihydro-isoindole-2-sulfonyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
72	2-[4-(2,3-Dihydro-indole-1-sulfonyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
73	(±)-2-[4-(1-Phenyl-ethylsulfamoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
74	(±)-2-[4-(1,2,3,4-Tetrahydro-naphthalen-1-ylsulfamoyl)-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
75	2-{4-[(Thiophen-2-ylmethyl)-sulfamoyl]-phenyl}-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;
76	2-{4-[(Furan-2-ylmethyl)-sulfamoyl]-phenyl}-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide;

77	2-{4-[(Pyridin-4-ylmethyl)-sulfamoyl]-phenyl}-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide; and
78	2-[4-(<i>S</i>)-Indan-1-ylsulfamoyl]-phenyl]-1 <i>H</i> -benzoimidazole-5-carboxylic acid amide.

Also preferred are compounds selected from the group consisting of: 2-{4-[1-(4-Chloro-phenyl)-vinyl]-phenyl}-1*H*-imidazo[4,5-*b*]pyridine-5-carboxylic acid amide; 2-{4-[(2,4-Dichloro-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(3,4-Dihydro-1*H*-isoquinoline-2-sulfonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-(4-Thiophen-2-ylmethyl-phenyl)-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Furan-3-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Furan-3-yl-hydroxy-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-(4-Furan-3-ylmethyl-phenyl)-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(1-Methyl-1*H*-imidazole-2-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[Hydroxy-(1-methyl-1*H*-imidazol-2-yl)-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(1-Methyl-1*H*-imidazol-2-ylmethyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(5-Chloro-thiophene-2-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(5-Chloro-thiophen-2-yl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(5-Chloro-thiophen-2-ylmethyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Piperidine-4-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-piperidin-4-yl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-(4-Piperidin-4-ylmethyl-phenyl)-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Tetrahydro-thiopyran-4-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[Hydroxy-(tetrahydro-thiopyran-4-yl)-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Tetrahydro-thiopyran-4-ylmethyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Tetrahydro-pyran-4-ylmethyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; [[4-(5-Carbamoyl-1*H*-benzoimidazol-2-yl)-phenyl]-(4-chloro-phenyl)-methoxy]-acetic acid; 2-{4-[(2-Amino-ethoxy)-(4-chloro-phenyl)-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(4-Chloro-phenyl)-difluoro-methyl]-phenyl}-1*H*-

benzoimidazole-5-carboxylic acid amide; 2-[4-(Benzo[1,3]dioxol-5-yl-difluoromethyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[1-(4-Chlorophenyl)-1-methyl-ethyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(4-Chloro-phenyl)-cyano-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-((*S*)-1-Hydroxymethyl-1,3-dihydro-isoindole-2-sulfonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(*R*)-1-Hydroxymethyl-1,3-dihydro-isoindole-2-sulfonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-((1*R*,2*S*)-2-Hydroxy-indan-1-ylsulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-((*S*)-2-Hydroxy-1-phenylethylsulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-((*R*)-2-Hydroxy-1-phenylethylsulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; and 2-{4-[(Pyridin-2-ylmethyl)-sulfamoyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide.

More preferred are compounds selected from the group consisting of:

2-[4-(4-Methyl-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Naphthalene-2-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(4-Chloro-3-trifluoromethyl-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(3-Bromo-4,5-dimethoxy-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(3,4-Dichloro-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(3,4-Dimethyl-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(4-Ethyl-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-(4-Cyclohexanecarbonyl-phenyl)-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-phenyl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(4-Chloro-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-*p*-tolyl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-[Hydroxy-(4-methoxy-phenyl)-methyl]-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxynaphthalen-2-yl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(4-Chloro-3-trifluoromethyl-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(3,4-Dichloro-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(3,4-Dimethyl-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid

amide; 2-{4-[(4-Ethyl-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Benzo[1,3]dioxol-5-yl-hydroxy-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-quinolin-3-yl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(4-Chloro-benzyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-(4-Naphthalen-2-ylmethyl-phenyl)-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(3,4-Dimethyl-benzyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(4-Ethyl-benzyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[1-(4-Chloro-phenyl)-vinyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[1-(4-Chloro-phenyl)-ethyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(1,3-Dihydro-isoindole-2-sulfonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(2,3-Dihydro-indole-1-sulfonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; (±)-2-[4-(1,2,3,4-Tetrahydro-naphthalen-1-ylsulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(Thiophen-2-ylmethyl)-sulfamoyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; and 2-[4-(Indan(S)-1-ylsulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide.

Most preferred are compounds selected from the group consisting of: 2-[4-(Naphthalene-2-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(3,4-Dichloro-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(4-Chloro-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-naphthalen-2-yl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(4-Chloro-3-trifluoromethyl-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(3,4-Dichloro-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(3,4-Dimethyl-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-quinolin-3-yl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(4-Chloro-benzyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-(4-Naphthalen-2-ylmethyl-phenyl)-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(3,4-Dimethyl-benzyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[1-(4-Chloro-phenyl)-vinyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid

amide; 2-{4-[1-(4-Chloro-phenyl)-ethyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(1,3-Dihydro-isoindole-2-sulfonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; and 2-[4-(*S*)-Indan-1-ylsulfamoyl]-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide.

- 5 Most preferred are compounds selected from the group consisting of: 2-[4-(Hydroxy-phenyl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(4-Chloro-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-*p*-tolyl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[Hydroxy-(4-methoxy-phenyl)-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-naphthalen-2-yl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(4-Chloro-3-trifluoromethyl-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(3-Bromo-4,5-dimethoxy-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide;
- 10 2-{4-[(3,4-Dichloro-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(3,4-Dimethyl-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(4-Ethyl-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Benzo[1,3]dioxol-5-yl-hydroxy-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-quinolin-3-yl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-pyridin-4-yl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Cyclohexyl-hydroxy-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid
- 20 amide; 2-{4-[Hydroxy-(tetrahydro-pyran-4-yl)-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-thiophen-2-yl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(6-Chloro-benzo[1,3]dioxol-5-yl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(2-Chloro-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(2,4-Dichloro-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[Hydroxy-(2-methoxy-phenyl)-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-*o*-tolyl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid
- 25 30

amide; and 2-{4-[(2,4-Dichloro-phenyl)-hydroxy-methyl]-phenyl}-1H-benzimidazole-5-carboxylic acid amide.

Related Compounds

5 The invention provides the disclosed compounds and closely related, pharmaceutically acceptable forms of the disclosed compounds, such as salts, esters, amides, acids, hydrates or solvated forms thereof; masked or protected forms; and racemic mixtures, or enantiomerically or optically pure forms. Related compounds also include compounds of the invention that have been
10 modified to be detectable, e.g., isotopically labelled with ^{11}C , or ^{18}F for use as a molecular probe in positron emission tomography (PET) or single-photon emission computed tomography (SPECT).

 The invention also includes disclosed compounds having one or more functional groups (e.g., hydroxyl, amino, or carboxyl) masked by a protecting
15 group. See, e.g., Greene and Wuts, Protective Groups in Organic Synthesis, 3rd ed., (1999) John Wiley & Sons, NY. Some of these masked or protected compounds are pharmaceutically acceptable; others will be useful as intermediates. Synthetic intermediates and processes disclosed herein, and minor modifications thereof, are also within the scope of the invention.

20

C. Synthetic Methods

 The invention provides methods of making the disclosed compounds according to traditional organic synthetic methods as well as matrix or combinatorial synthetic methods. Schemes 1 through 9 describe suggested
25 synthetic routes. Using these Schemes, the guidelines below, and the examples, a person of skill in the art may develop analogous or similar methods for a given compound that are within the invention.


 One skilled in the art will recognize that synthesis of the compounds of the present invention may be effected by purchasing an intermediate or
30 protected intermediate compounds described in any of the schemes disclosed herein. One skilled in the art will further recognize that during any of the processes for preparation of the compounds in the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the

molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in "Protective Groups in Organic Synthesis", John Wiley & Sons, 1991. These protecting groups may be removed at a convenient stage using methods known from the art.

5 Examples of the described synthetic routes include Synthetic Examples 1 through 78. Compounds analogous to the target compounds of these examples can be, and in many cases, have been, made according to similar routes. The disclosed compounds are useful in basic research and as pharmaceutical agents as described in the next section.

10 Broadly, compounds of formula I may be made according to Scheme 1. Aldehyde (III) can be condensed with diamine (II) in the presence of an oxidizing agent such as $\text{Na}_2\text{S}_2\text{O}_5$ to provide benzimidazoles (I). This reaction takes place in a solvent, such as DMA or DMF, with the application of heat. Better yields might be obtained where the reaction is heated to a temperature
15 of from 80 °C to 100 °C. However in the case that Z is a carbonyl, better yields are obtained at a reaction temperature of 60 °C. Compounds where Z contains an alcohol form a dimer in this reaction, which must be hydrolyzed in the presence of water and an acid at elevated temperatures. Improved yields for compounds where Z is an alcohol may be obtained as described below for
20 Scheme 6.

Scheme 1




25 Schemes 2, 3, 4 and 5 show the formation of various aldehyde (III) subtypes. Referring to Scheme 2, a ketone (IV) may be protected to form, for example, a dioxolane. Lithium halogen exchange of the bromide with a suitable alkyl lithium reagent such as $n\text{-BuLi}$, followed by a DMF quench will produce aldehyde (IIIa). Other protecting groups amenable to lithium halogen

exchange chemistry may also be employed. In this regard, reference is made to "Protective Groups in Organic Synthesis", John Wiley & Sons, 1991.


Deprotection of the ketone protecting group, in this case with a suitable acid such as perchloric acid, affords aldehyde (IIIb). Other functional groups in A or in R_c that are sensitive to chemistry utilizing butyl lithium should be protected. For example, a carbonyl group should be protected as the ketal as described for Z.

Scheme 2




Referring to Scheme 3, anilines (V) may be halogenated in the para position by treatment with a brominating agent such as N-bromosuccinimide. Lithium halogen exchange as described above followed by a DMF quench can be used to produce aldehydes of type (IIIc). Groups in A or in R_c that are sensitive to chemistry utilizing butyl lithium should be protected. For example, a carbonyl group should be protected as the ketal as described for Z. In one alternative to Scheme 3, a phenyl alkyl amine may be cross-coupled with 4-bromobenzaldehyde in the presence of a palladium catalyst to produce aldehyde (IIIc).

Scheme 3




Referring to Scheme 4, an aldehyde/ketone (VI) undergoes a Grignard reaction with an appropriate Grignard reagent (VII) that contains a masked aldehyde to produce bicyclic alcohol (VIII). Where X_1 is hydrogen, alcohol (VII) is oxidized and deprotected to the aldehyde (IIIb). Where there are groups in A


or R_c that are sensitive to oxidation, mild oxidation conditions should be employed such as TEMPO or PDC or an appropriate protecting group should be employed. Where X_1 is alkyl, alcohol (VII) is exposed to perchloric acid, allowing for deprotection of the aldehyde in addition to dehydration of the alcohol to form aldehyde (IIIId). Hydrogenation of the double bond in compounds of formula (I) derived from (IIIId) can lead to alternative embodiments of formula (I) in which Z is $>CR_dR_d$. Where there are groups in A or R_c that are sensitive to oxidation, mild deprotection conditions should be employed conc. HCl in THF. Where X_1 is hydrogen, alcohol (VII) is exposed to a protic acid which deprotects to form aldehyde (IIIe). Where there are groups in A or R_c that are sensitive to oxidizing conditions, non-oxidizing acids should be used for the deprotection such as HCl.



Referring to Scheme 5, substituted amine (X) is sulfonylated with a formylated benzene sulfonyl chloride derivative (IX) to produce aldehyde (IIIIf). In the case that X_1 , R_c or A contains a primary alcohol then this alcohol should be protected with an acid sensitive protecting group, such as a silyl ether. The bicyclic A fused sulfonamides may be produced in Scheme 5 where the depicted cyclic substituted amine is replaced with an amine of the formula




Scheme 5



5


- Referring to Scheme 6, compounds of formula (XIb) can be obtained by reducing compounds of formula (XIa) with NaBH_4 , LiBH_4 , $\text{Na}(\text{OAc})_3\text{BH}$, DIBAL-H or other reducing agent. Compounds of formula (XIb) may be further reduced with reducing agents, including NaBH_4 , triethylsilylhydride, TES-Cl or TMS-Cl to obtain compounds of formula (XIc). Compounds of formula (XIb) may be alkylated to form compounds of formula (XI d) by various methods. In the depicted method, the alcohol is converted to a good leaving group, such as a chloride, using either HCl or SOCl_2 , and the resulting benzyl chloride may be displaced with a variety of alcohols to produce the corresponding ether (XI d).
- 15 In another method, a base, such as NaH , is used with an alkylating agent, such as MeI , to form a methyl ether. The desired R_e may be obtained with various alkylating agents. Compounds of formula (XIb) may be aminated to form compounds of formula (XI e) by first forming the chloride with chlorinating agents such as SOCl_2 or HCl and subsequently displacing the chloride with the
- 20 appropriate amine.

Scheme 6




- Referring to Scheme 7, compounds of formula (Xlg) can be obtained by
- 5 nucleophilic addition of an appropriate Grignard or lithium reagent to compound (Xla). The resulting tertiary alcohol may then be converted to ethers or amines of type (Xlh) or (Xlj) using the methods described in Scheme 6. Compounds of formula (Xlg) can also be converted into analogs of formula (IIId) in Scheme 4 by treatment with perchloric acid. The resulting double bond
 - 10 can be hydrogenated to access alternative embodiments of formula (I) in which Z is $>\text{CR}_d\text{R}_d$.

Scheme 7



Referring to Scheme 8, the carboxylic acid of formula (XII) can be converted to an amide by treatment with 1,1'-carbonyldiimidazole (CDI), or other similar activating agent, followed by a nucleophilic amine to provide compounds of formula (XIII). Standard peptide coupling conditions known to one skilled in the art are also applicable.

Scheme 8




10

Compounds of general formula (XIX) can be synthesized using the methods outlined in Scheme 9. Treatment of pyridine (XIV) with an ammonium equivalent such as (NH₄)₂CO₃ provides 2-aminopyridine (XV). Removal of the methyl group in (XV) with hydrobromic acid and acetic acid, followed by conversion to the bromide using a nucleophilic bromide source such as (C₄H₉)₄N⁺Br⁻, in the presence of P₂O₅, gives compound (XVI). Treatment of the bromide with a metallic cyanide such as CuCN then results in the formation of compound (XVII). Reduction of the nitro group of (XVII) using H₂ and Pd or other reducing agent, followed by condensation with an aryl aldehyde of type (III) in the presence of an oxidizing agent such as Na₂S₂O₅ provides

20

imidazopyridines of general formula (XVIII). The cyano group of (XVIII) can then be converted to an amide of formula (XIX) by hydrolysis with BF_3 in acetic acid.

Scheme 9



5

D. Formulation and Administration

The present compounds inhibit the checkpoint modulator Cds1 and therefore are useful as a medicine especially in methods for treating patients suffering from disorders or conditions that are modulated or regulated by Cds1, such as cancer.

The invention features a method for treating a subject with cancer, said method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound of the invention. The invention also provides a method for inhibiting Cds1 activity in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound of the invention.

The compounds of the present invention may be formulated into various pharmaceutical forms for administration purposes. To prepare these pharmaceutical compositions, an effective amount of a particular compound, in

base or acid addition salt form, as the active ingredient is intimately mixed with a pharmaceutically acceptable carrier.

A carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for oral administration, intravenous injection or parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. These include water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. In view of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are generally employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Such additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. Acid addition salts of the compounds of formula I, due to their increased water solubility over the corresponding base form, are more suitable in the preparation of aqueous compositions.


It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification herein

refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.


Pharmaceutically acceptable acid addition salts include the therapeutically active non-toxic acid addition salt forms that the disclosed compounds are able to form. The latter can conveniently be obtained by treating the base form with an appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-aminosalicylic, palmoic and the like acids. The term addition salt also comprises the solvates that the disclosed compounds, as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like. Conversely the salt form can be converted by treatment with alkali into the free base form.

"Stereoisomeric forms" defines all the possible isomeric forms that the compounds of formula (I) may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure. More in particular, stereogenic centers may have the (R)- or (S)-configuration; substituents on bivalent cyclic saturated radicals may have either the cis- or trans-configuration. The invention encompasses stereochemically isomeric forms including diastereoisomers, as well as mixtures thereof in any proportion of the disclosed compounds. The disclosed compounds may also exist in their tautomeric forms. Such forms although not explicitly indicated in the above and following formulae are intended to be included within the scope of the

present invention. For example, the present invention includes



2-[4-(4-Chloro-benzoyl)]-1*H*-benzoimidazole-5-carboxylic acid amide
as well as



2-[4-(4-Chloro-benzoyl)]-3*H*-benzoimidazole-5-carboxylic acid amide.

Those of skill in the treatment of disorders or conditions mediated by the Cds1 enzyme could easily determine the effective daily amount from the test results presented hereinafter and other information. In general it is

contemplated that a therapeutically effective dose would be from 0.001 mg/kg to 100 mg/kg body weight, more preferably from 1 mg/kg to 50 mg/kg body weight. It may be appropriate to administer the therapeutically effective dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 1 mg to 2000 mg, and in particular 10 to 500 mg of active ingredient per unit dosage form. Examples include 10 mg, 25 mg, 50 mg, 100 mg, 150 mg, 250 mg, and 500 mg dosage forms. Compounds of the invention may also be prepared in time-release or subcutaneous or transdermal patch formulations. Disclosed compound may also be formulated as a spray or other topical or inhalable formulations.

The exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight and general physical condition of the particular patient as well as other medication the patient may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated patient and/or depending on the evaluation of the

physician prescribing the compounds of the instant invention. The effective daily amount ranges mentioned herein are therefore only guidelines.

The next section includes detailed information relating to the use of the disclosed compounds.

5

E. Examples

General Experimental:

NMR spectra were obtained on either a Bruker model DPX400 (400
10 MHz) or DPX500 (500 MHz) spectrometer. The format of the ¹H NMR data below is: chemical shift in ppm down field of the tetramethylsilane reference (multiplicity, coupling constant *J* in Hz, integration).

Mass spectra were obtained on an Agilent series 1100 MSD using electrospray ionization (ESI) in either positive or negative mode as indicated.

15 HPLC retention times are reported in minutes, using the methods and conditions reported below.

Method A:


Instrument: Agilent HP-1100
Solvent: Acetonitrile (0.05% trifluoroacetic acid, TFA)/H₂O (0.05% TFA)
20 Flow rate: 0.75 mL/min
Gradient: 1 min at 1% H₂O; 7 min linear ramp to 99% H₂O; 4 min at 99% H₂O.
Column: ZORBAX Eclipse XDB-C8 (5 μm, 4.6x150 mm)
Temperature: 35 °C
25 Wavelength: Dual detection at 220 and 254 nM.

Method B:

Instrument: Agilent HP-1100
Solvent: Acetonitrile (0.05% trifluoroacetic acid, TFA)/H₂O (0.05% TFA)
Flow rate: 1.5 mL/min
30 Gradient: 1 min at 1% H₂O; 3.5 min linear ramp to 99% H₂O; 1.5 min at 99% H₂O
Column: XTerra® RP₁₈ (4.6x50 mm)
Temperature: 35 °C

- Wavelength: Dual detection at 220 and 254 nM.
Method C:
Instrument: Agilent HP-1100
Solvent: Acetonitrile (0.05% TFA)/H₂O (0.05% TFA)
5 Flow rate: 1.0 mL/min
Gradient: 10% Acetonitrile; 5 min linear ramp to 100% Acetonitrile; 5 min at 100% Acetonitrile.
Column: Phenomenex Luna® C18 (5 μ m, 4.6x150 mm)
Temperature: 24 °C
10 Wavelength: Detection at 230, 254 and 280 nM.

Example 1




- 2-[4-(2-Phenyl-[1,3]dioxolan-2-yl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid
15 amide
A. 2-(4-Bromo-phenyl)-2-phenyl-[1,3]dioxolane. To a solution of (4-bromo-phenyl)-phenyl-methanone (5.0 g, 19.1 mmol) in anhydrous toluene under N₂ was added ethylene glycol (5.32 mL, 95.5 mmol). The reaction mixture was heated to reflux for 10 h under a Dean-Stark trap. The mixture was cooled to
20 room temperature (RT), washed with 1 N sodium hydroxide (100 mL) and H₂O (100 mL), and dried (MgSO₄). Solvent was removed under reduced pressure, yielding the title compound as a solid (2.89 g, 49%).
B. 4-(2-Phenyl-[1,3]dioxolan-2-yl)-benzaldehyde. To a solution of 2-(4-bromo-phenyl)-2-phenyl-[1,3]dioxolane (500 mg, 1.6 mmol) cooled to -78 °C in
25 anhydrous tetrahydrofuran (THF) (100 mL) under N₂ was added *n*-butyllithium (1.1 mL of 1.6 M in hexanes, 1.7 mmol) dropwise. The reaction mixture was stirred at -78 °C for 30 min, then dimethylformamide (DMF) (0.135 mL, 1.7 mmol) was added dropwise, and the mixture was allowed to warm to RT. The mixture was poured into saturated aqueous NH₄Cl, and the resulting mixture

was extracted with diethyl ether (Et₂O) (2 X 100 mL). The combined extracts were washed with brine (100 mL) and dried (Na₂SO₄). The solvent was removed under reduced pressure. The title compound was obtained as an oil (350 mg, 84%). ¹H NMR (400 MHz, CDCl₃): δ 9.99 (s, 1H), 7.84 (d, *J* = 8.5 Hz, 2H), 7.71 (d, *J* = 8.2 Hz, 2H), 7.52-7.49 (dd, *J* = 8.4, 1.5 Hz, 2H), 7.36-7.29 (m, 4H), 4.12-4.04 (m, 4H).

C. 2-[4-(2-Phenyl-[1,3]dioxolan-2-yl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide. To a solution of 3,4-diamino-benzamide (100 mg, 0.6 mmol) in anhydrous DMF was added 4-(2-phenyl-[1,3]dioxolan-2-yl)-benzaldehyde (168 mg, 0.6 mmol) and sodium metabisulfite (164 mg, 0.86 mmol). The mixture was heated to 90 °C under N₂ for 16 h. The reaction mixture was cooled and added dropwise to ice/H₂O. The resulting solids were filtered and washed with H₂O (50 mL) then hexanes (2 X 50 mL). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 160 mg (63%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.3. HPLC (Method A): R_t = 7.02. MS (ESI⁺): mass calculated for C₂₃H₁₉N₃O₃, 385.1; *m/z* found, 386.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD): δ 8.13 (br s, 1H), 8.04 (d, *J* = 8.4 Hz, 2H), 7.77 (d, *J* = 8.5 Hz, 1H), 7.64 (d, *J* = 8.4 Hz, 2H), 7.58 (br s, 1H), 7.49-7.47 (dd, *J* = 8.4, 1.5 Hz, 2H), 7.32-7.23 (m, 3H), 4.03 (s, 4H).

Example 2



2-[4-[2-(4-Chloro-phenyl)-[1,3]dioxolan-2-yl]-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

A. 2-(4-Bromo-phenyl)-2-(4'-chloro-phenyl)-[1,3]dioxolane. This compound was prepared as described in Example 1 substituting (4-bromo-phenyl)-(4-chloro-phenyl)-methanone (750 mg, 2.5 mmol) for (4-bromo-phenyl)-phenyl-methanone in Step A. The title compound was recrystallized from ethanol to


afford 680 mg (85%) of white plates. ^1H NMR (400 MHz, CDCl_3): δ 7.45 (d, J = 8.7 Hz, 2H), 7.41 (d, J = 8.7 Hz, 2H), 7.35 (d, J = 8.7 Hz, 2H), 7.29 (d, J = 8.7 Hz, 2H), 4.04 (m, 4H).

B. 4-[2-(4-Chloro-phenyl)-[1,3]dioxolan-2-yl]-benzaldehyde. This compound was prepared as described in Example 1 substituting 2-(4-bromo-phenyl)-2-(4-chloro-phenyl)-[1,3]dioxolane (300 mg, 0.8 mmol) for 2-(4-bromo-phenyl)-2-phenyl-[1,3]dioxolane in Step B. Purification by chromatography (silica gel, CH_2Cl_2) afforded 100 mg (39%) of the title compound. ^1H NMR (400 MHz, CDCl_3): δ 10.00 (s, 1H), 7.85 (d, J = 8.4 Hz, 2H), 7.67 (d, J = 8.3 Hz, 2H), 7.45 (d, J = 8.6 Hz, 2H), 7.30 (d, J = 8.6 Hz, 2H), 4.07 (m, 4H).

C. 2-{4-[2-(4-Chloro-phenyl)-[1,3]dioxolan-2-yl]-phenyl}-1H-benzoimidazole-5-carboxylic acid. This compound was prepared as described in Example 1 Step C from 4-[2-(4-chloro-phenyl)-[1,3]dioxolan-2-yl]-benzaldehyde (100 mg, 0.34 mmol) and 3,4-diamino-benzoic acid (53 mg, 0.34 mmol). The title compound was obtained as a tan solid 135 mg (92%). MS (ESI): mass calculated for $\text{C}_{23}\text{H}_{17}\text{ClN}_2\text{O}_4$, 420.1; m/z found, 421.1 $[\text{M}+\text{H}]^+$, 419.1 $[\text{M}-\text{H}]^-$. HPLC (Method B): R_t = 2.43.

D. 2-[4-(2-Phenyl-[1,3]dioxolan-2-yl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide. To a solution of 2-{4-[2-(4-chloro-phenyl)-[1,3]dioxolan-2-yl]-phenyl}-1H-benzoimidazole-5-carboxylic acid (135 mg, 0.32 mmol) in anhydrous DMF was added carbonyldiimidazole (118 mg, 0.73 mmol). The reaction mixture was stirred under N_2 for 30 min and then cooled to 0 °C, and ammonium bicarbonate (140 mg, 1.4 mmol) was added. The resulting mixture was allowed to warm to RT and was stirred for 16 h. The mixture was added dropwise to saturated aqueous NH_4Cl . The resulting precipitate was collected by filtration and washed with H_2O (100 mL) then hexanes (100 mL). The product was dried under vacuum overnight to give the title compound (102 mg, 76%). TLC (silica, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2): R_f = 0.33. HPLC (Method A): R_t = 7.42. MS (ESI+): mass calculated for $\text{C}_{23}\text{H}_{18}\text{ClN}_3\text{O}_3$, 419.1; m/z found, 420.1 $[\text{M}+\text{H}]^+$. ^1H NMR (400 MHz, CD_3OD): δ 8.09 (s, 1H), 8.00 (d, J = 8.4 Hz, 2H), 7.75-7.72 (dd, J = 8.5, 1.5 Hz, 1H), 7.59 (d, J = 8.4 Hz, 2H), 7.56 (br d, J = 8.7 Hz, 1H), 7.43 (d, J = 8.5 Hz, 2H), 7.27 (d, J = 8.6 Hz, 2H), 3.99 (s, 4H).

Example 3


2-(4-Benzoyl-phenyl)-1*H*-benzoimidazole-5-carboxylic acid amide

- A. 4-Benzoyl-benzaldehyde. To a cooled (ice/acetone) solution of 4-(2-phenyl-[1,3]dioxolan-2-yl)-benzaldehyde (145 mg, 0.57 mmol) in CH₂Cl₂ was added dropwise perchloric acid (70%, 0.38 mL). The reaction mixture was stirred at RT for 2 h, and then was poured into saturated aqueous NaHCO₃ (75 mL). The aqueous layer was extracted with CH₂Cl₂. The combined organic layers were washed with H₂O (2 X 50 mL) and dried (Na₂SO₄). The solvent was removed under reduced pressure to provide 100 mg (83%) of the title compound. ¹H NMR (400 MHz, CDCl₃): δ 10.14 (s, 1H), 8.01 (d, *J* = 8.4 Hz, 2H), 7.93 (d, *J* = 8.2 Hz, 2H), 7.83-7.80 (dd, *J* = 8.4, 1.3 Hz, 2H), 7.63 (d, *J* = 7.4 Hz, 1H), 7.52 (t, *J* = 7.6 Hz, 2H).

- B. 2-(4-Benzoyl-phenyl)-1*H*-benzoimidazole-5-carboxylic acid. This compound was prepared as described in Example 1 using 4-benzoyl-benzaldehyde (100 mg, 0.47 mmol) and 3,4-diamino-benzoic acid (72 mg, 0.47 mmol) in Step C. The title compound was obtained as a tan solid (135 mg, 85%). MS (ESI): mass calculated for C₂₁H₁₄N₂O₃, 342.1; *m/z* found, 342.9 [M+H]⁺. HPLC (Method A): *R*_t = 7.17.

- C. 2-(4-Benzoyl-phenyl)-1*H*-benzoimidazole-5-carboxylic acid amide. This compound was prepared as described in Example 2 using 2-(4-benzoyl-phenyl)-1*H*-benzoimidazole-5-carboxylic acid (138 mg, 0.4 mmol) in Step D. The title compound was obtained as a tan solid (54 mg, 39%). TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): *R*_f = 0.31. HPLC (Method A): *R*_t = 6.75. MS (ESI⁺): mass calculated for C₂₁H₁₅N₃O₂, 341.1; *m/z* found, 342.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD): δ 8.19 (d, *J* = 8.2 Hz, 2H), 8.16 (br s, 1H), 7.87 (d, *J* = 8.3 Hz, 2H), 7.80-7.78 (dd, *J* = 8.5, 1.6 Hz, 1H), 7.76 (d, *J* = 8.4 Hz, 2H), 7.62-7.60 (m, 2H), 7.49 (t, *J* = 7.5 Hz, 2H), 7.00 (s, 1H).

Example 4



2-[4-(4-Chloro-benzoyl)-phenyl]-1*H*-benzimidazole-5-carboxylic acid amide

A. (4-Chloro-phenyl)-(4-[1,3]dioxolan-2-yl-phenyl)-methanol. To a solution of
 5 4-chloro-benzaldehyde (1.98 g, 14.0 mmol) in anhydrous THF, cooled to
 -78 °C, was added 4-(1,3-dioxolan-2-yl)phenylmagnesium bromide (60 mL,
 0.25 M in THF) dropwise. The reaction mixture was stirred 1 h at -78 °C then
 quenched with saturated aqueous NH₄Cl (50 mL). The resulting mixture was
 extracted with Et₂O (2 X 100 mL). The combined extracts were washed with
 10 H₂O (100 mL) then brine (100 mL), and dried (MgSO₄). Solvent was removed
 under reduced pressure, and the residue was purified by chromatography
 (silica gel, 50% ethyl acetate/hexanes) to afford the title compound (3.25 g,
 79%). TLC (silica, 50% ethyl acetate/hexanes): R_f = 0.4. ¹H NMR (500 MHz,
 CDCl₃): δ 7.45 (d, *J* = 8.2 Hz, 2H), 7.36 (d, *J* = 8.1 Hz, 2H), 7.29 (s, 4H), 5.82
 15 (d, *J* = 3.3 Hz, 1H), 4.14-4.08 (m, 2H), 4.06-4.01 (m, 2H).


B. (4-Chloro-phenyl)-(4-[1,3]dioxolan-2-yl-phenyl)-methanone. (4-Chloro-
 phenyl)-(4-[1,3]dioxolan-2-yl-phenyl)-methanol (250 mg, 0.85mmol) was
 dissolved in ethyl acetate (1.5 mL) and treated with a solution of sodium
 bromide (88 mg, 0.85 mmol) in saturated aqueous NaHCO₃ (2.3 mL). The
 20 reaction mixture was cooled to 0 °C and stirred for 30 min. Free radical
 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) (1.3 mg, 0.008 mmol) and then
 aqueous sodium hypochlorite solution (1.25 mL, 0.67 M) were added, and the
 resulting mixture was stirred for 2 h. Ethyl acetate (100 mL) and brine (100
 mL) were added, and the mixture was stirred 5 min. The organic layer was
 25 washed with brine (2 X 75 mL) and then dried (Na₂SO₄). Solvent was removed
 under reduced pressure yielding the title compound as an off-white solid (247
 mg, 99%). TLC (silica, 50% ethyl acetate/hexanes): R_f = 0.5. HPLC (Method
 A): R_t = 9.99. MS (ESI⁺): mass calculated for C₁₆H₁₃ClO₃, 288.0; *m/z* found,
 289.0 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃): δ 7.78 (d, *J* = 8.3 Hz, 2H), 7.75 (d, *J*

= 8.6 Hz, 2H), 7.61(d, J = 8.1 Hz, 2H), 7.46 (d, J = 8.6 Hz, 1H), 5.89 (s, 1H), 4.16-4.12 (m, 2H), 4.11-4.06 (m, 2H).

C. 4-(4-Chloro-benzoyl)-benzaldehyde. This compound was prepared as described in Example 3 using (4-chloro-phenyl)-(4-[1,3]dioxolan-2-yl-phenyl)-methanone in Step A. TLC (silica, 50% ethyl acetate/hexanes): R_f = 0.6. HPLC (Method A): R_t = 9.93. MS (ESI+): mass calculated for $C_{14}H_9ClO_2$, 244.0; m/z found, 245.0 $[M+H]^+$. 1H NMR (500 MHz, $CDCl_3$): δ 10.13 (s, 1H), 8.01 (d, J = 8.4 Hz, 2H), 7.90 (d, J = 8.2 Hz, 2H), 7.76 (d, J = 8.6 Hz, 2H), 7.49 (d, J = 8.6 Hz, 2H).

10 D. 2-[4-(4-Chloro-benzoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide. To a solution of 3,4-diamino-benzamide (92 mg, 0.6 mmol) in anhydrous dimethylacetamide (DMA) (10 mL) was added 4-(4-chloro-benzoyl)-benzaldehyde (150 mg, 0.6 mmol) and sodium metabisulfite (151 mg, 0.79 mmol). The mixture was heated to 60 °C under N_2 for 16 h. The reaction mixture was cooled and added dropwise to ice/ H_2O . The resulting solids were filtered and washed with H_2O (50 mL) then hexanes (2 X 50 mL). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2) afforded 71 mg (31%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2): R_f = 0.3. HPLC (Method A): R_t = 7.53. MS (ESI+): mass calculated for $C_{21}H_{14}ClN_3O_2$, 375.1; m/z found, 376.0, $[M+H]^+$. 1H NMR (500 MHz, $DMSO-d_6$): δ 13.35 (br s, 1H), 8.38 (d, J = 8.3 Hz, 2H), 8.01 (br s, 1H), 7.94 (d, J = 8.3 Hz, 2H), 7.82 (d, J = 8.4 Hz, 3H), 7.67 (d, J = 8.4 Hz, 3H), 7.30 (br s, 1H).


Example 5



25 2-[4-(4-Methyl-benzoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide
The title compound was prepared as described in Example 4 substituting 4-methyl-benzaldehyde for 4-chloro-benzaldehyde in Step A. TLC (silica, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2): R_f = 0.29. HPLC

(Method A): $R_t = 7.36$. MS (ESI+): mass calculated for $C_{22}H_{17}N_3O_2$, 355.1; m/z found, 356.1 $[M+H]^+$. 1H NMR (500 MHz, CD_3OD): δ 8.26 (d, $J = 8.5$ Hz, 2H), 8.25 (br s, 1H), 7.93 (d, $J = 8.5$ Hz, 2H), 7.85 (d, $J = 8.4$ Hz, 1H), 7.74 (d, $J = 8.2$ Hz, 2H), 7.69 (br s, 1H), 7.38 (d, $J = 7.8$ Hz, 2H), 2.46 (s, 3H).


5 Example 6



2-[4-(4-Methoxy-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 4 substituting 4-methoxy-benzaldehyde for 4-chloro-benzaldehyde in Step A. TLC (silica, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2): $R_f = 0.27$. HPLC (Method A): $R_t = 7.09$. MS (ESI+): mass calculated for $C_{22}H_{17}N_3O_3$, 371.1; m/z found, 372.1 $[M+H]^+$. 1H NMR (500 MHz, CD_3OD): δ 8.25 (d, $J = 8.4$ Hz, 3H), 7.89 (d, $J = 8.4$ Hz, 2H), 7.84 (d, $J = 8.9$ Hz, 3H), 7.68 (br s, 1H), 7.07 (d, $J = 8.9$ Hz, 2H), 3.90 (s, 3H).

15 Example 7




2-[4-(Naphthalene-2-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 4 substituting naphthalene-2-carbaldehyde for 4-chloro-benzaldehyde in Step A. TLC (silica, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2): $R_f = 0.25$. HPLC (Method A): $R_t = 7.74$. MS (ESI+): mass calculated for $C_{25}H_{17}N_3O_2$, 391.1; m/z found, 392.1 $[M+H]^+$. 1H NMR (500 MHz, CD_3OD): δ 8.30 (s, 1H), 8.27 (d, $J = 8.4$ Hz, 2H), 8.23 (br s, 1H), 8.02-7.95 (m, 5H), 7.92-7.90 (dd, $J = 8.5, 1.6$ Hz,

1H), 7.85 (br d, $J = 7.8$ Hz, 1H), 7.68 (br s, 1H), 7.66-7.62 (td, $J = 7.5, 1.1$ Hz, 1H), 7.59-7.56 (td, $J = 7.5, 1.1$ Hz, 1H).

Example 8




5 2-[4-(4-Chloro-3-trifluoromethyl-benzoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 4 substituting 4-chloro-3-trifluoromethyl-benzaldehyde for 4-chloro-benzaldehyde in Step A.

TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): $R_f =$

10 0.25. HPLC (Method A): $R_t = 8.20$. MS (ESI-): mass calculated for C₂₂H₁₃ClF₃N₃O₂, 443.1; m/z found, 442.5 [M-H]⁻. ¹H NMR (500 MHz, CD₃OD): δ 8.30 (d, $J = 8.5$ Hz, 2H), 8.23 (br s, 1H), 8.20 (d, $J = 1.9$ Hz, 1H), 8.05-8.03 (dd, $J = 8.2, 2.0$ Hz, 1H), 7.99 (d, $J = 8.6$ Hz, 2H), 7.86 (br d, $J = 8.3$ Hz, 1H), 7.83 (d, $J = 8.3$ Hz, 1H), 7.69 (br s, 1H).

15 Example 9



2-[4-(3-Bromo-4,5-dimethoxy-benzoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide

A. (3,4-Dimethoxy-phenyl)-(4-[1,3]dioxolan-2-yl-phenyl)-methanol. This

20 compound was prepared as described in Example 4 substituting 3,4-dimethoxy-benzaldehyde for 4-chloro-benzaldehyde in Step A. HPLC (Method A): $R_t = 8.01$. ¹H NMR (500 MHz, CDCl₃): δ 7.46 (d, $J = 8.2$ Hz, 2H), 7.40 (d, $J = 8.1$ Hz, 2H), 6.90 (d, $J = 1.9$ Hz, 1H), 6.87-6.85 (dd, $J = 8.3, 1.9$ Hz, 1H), 6.81

(d, $J = 8.2$ Hz, 1H), 5.81 (d, $J = 3.5$ Hz, 1H), 5.80 (s, 1H), 4.13-4.09 (m, 2H), 4.06-4.01 (m, 2H), 3.86 (s, 3H), 3.84 (s, 3H), 2.17-2.04 (m, 1H).

B. (3-Bromo-4,5-dimethoxy-phenyl)-(4-[1,3]dioxolan-2-yl-phenyl)-methanone.


To a solution of (3,4-dimethoxy-phenyl)-(4-[1,3]dioxolan-2-yl-phenyl)-methanol
5 (600 mg, 1.8 mmol) in ethyl acetate (5.0 mL) was added a solution of sodium bromide (253 mg, 2.4 mmol) in saturated aqueous NaHCO_3 (5.25 mL). The reaction mixture was cooled to 0 °C. TEMPO (3.0 mg, 0.018 mmol) and then aqueous sodium hypochlorite solution (2.9 mL, 0.67 M) were added, and the resulting mixture was stirred for 2 h. Ethyl acetate (100 mL) and brine (100
10 mL) were added, and the mixture was stirred 5 min. The organic layer was washed with brine (2 X 75 mL) and then dried (Na_2SO_4). The solvent was removed under reduced pressure. Purification by chromatography (silica gel, 50% ethyl acetate/hexanes) afforded 312 mg (42%) of the title compound. MS (ESI⁺): mass calculated for $\text{C}_{18}\text{H}_{17}\text{BrO}_5$, 392.0; m/z found, 394.0 $[\text{M}+\text{H}]^+$. ^1H
15 NMR (500 MHz, CDCl_3): δ 7.83 (d, $J = 8.3$ Hz, 2H), 7.58 (d, $J = 8.3$ Hz, 2H), 7.08 (s, 1H), 6.87 (s, 1H), 5.86 (s, 1H), 4.16-4.10 (m, 2H), 4.09-4.03 (m, 2H), 3.94 (s, 3H), 3.84 (s, 3H).

C. 4-(3-Bromo-4,5-dimethoxy-benzoyl)-benzaldehyde. This compound was prepared as described in Example 3 substituting (3-bromo-4,5-dimethoxy-
20 phenyl)-(4-[1,3]dioxolan-2-yl-phenyl)-methanone (300 mg, 0.7 mmol) for 4-(2-phenyl-[1,3]dioxolan-2-yl)-benzaldehyde in Step A. Purification by chromatography (silica gel, 50% ethyl acetate/hexanes) afforded 210 mg (79%) of the title compound. TLC (silica, 50% ethyl acetate/hexanes): $R_f = 0.47$. ^1H
NMR (500 MHz, CDCl_3): δ 10.12 (s, 1H), 8.01-7.91 (m, 4H), 7.09 (s, 1H), 6.94
25 (s, 1H), 3.95 (s, 3H), 3.87 (s, 3H).

D. 2-[4-(3-Bromo-4,5-dimethoxy-benzoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide. This compound was prepared as described in Example 4 substituting 4-(3-bromo-4,5-dimethoxy-benzoyl)-benzaldehyde (210 mg, 0.5
mmol) for 4-(4-chloro-benzoyl)-benzaldehyde in Step D. Purification by
30 chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2) afforded 236 mg (53%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2): $R_f = 0.45$. HPLC (Method A): $R_t = 7.45$. MS (ESI⁺): mass calculated for

$C_{23}H_{18}BrN_3O_4$, 479.0; m/z found, 480.0/482.0 $[M+H]^+$. 1H NMR (500 MHz, CD_3OD): δ 8.21 (br s, 1H), 8.20 (d, $J = 8.5$ Hz, 2H), 7.91 (d, $J = 8.5$ Hz, 2H), 7.84-7.82 (dd, $J = 8.5, 1.7$ Hz, 1H), 7.65 (d, $J = 8.3$ Hz, 1H), 7.21 (s, 1H), 7.04 (s, 1H), 3.90 (s, 3H), 3.82 (s, 3H).


5 Example 10



2-[4-(3,4-Dichloro-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 4 substituting 3,4-dichloro-benzaldehyde for 4-chloro-benzaldehyde in Step A. TLC (silica, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2): $R_f = 0.32$. MS (ESI+): mass calculated for $C_{21}H_{13}Cl_2N_3O_2$, 409.0; m/z found, 409.9/411.9 $[M+H]^+$. 1H NMR (500 MHz, CD_3OD): δ 8.20 (d, $J = 8.5$ Hz, 2H), 8.19 (br s, 1H), 7.89 (s, 1H), 7.88 (d, $J = 8.7$ Hz, 2H), 7.82-7.80 (dd, $J = 8.5, 1.6$ Hz, 1H), 7.68-7.62 (m, 3H).

15 Example 11




2-[4-(3,4-Dimethyl-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 4 substituting 3,4-dimethyl-benzaldehyde for 4-chloro-benzaldehyde in Step A. TLC (silica, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2): $R_f = 0.28$. HPLC (Method A): $R_t = 7.53$. MS (ESI+): mass calculated for $C_{23}H_{19}N_3O_2$, 369.1; m/z found, 370.1 $[M+H]^+$. 1H NMR (500 MHz, CD_3OD): δ 8.25 (d, $J = 8.4$ Hz, 2H), 8.22 (s, 1H), 7.91 (d, $J = 8.3$ Hz, 2H), 7.86-7.84 (dd, $J = 8.5, 1.6$ Hz, 1H), 7.68

(br d, $J = 8.4$ Hz, 1H), 7.60 (s, 1H), 7.53 (br d, $J = 7.7$ Hz, 1H), 7.30 (d, $J = 7.7$ Hz, 1H), 2.37 (s, 3H), 2.34 (s, 3H).


Example 12



5 2-[4-(4-Ethyl-benzoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 4 substituting 4-ethyl-benzaldehyde for 4-chloro-benzaldehyde in Step A. TLC (silica, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2): $R_f = 0.29$. HPLC (Method A): $R_t = 7.67$. MS (ESI+): mass calculated for $\text{C}_{23}\text{H}_{19}\text{N}_3\text{O}_2$, 369.1; m/z found, 370.1 $[\text{M}+\text{H}]^+$. ^1H NMR (500 MHz, CD_3OD): δ 8.24 (d, $J = 8.5$ Hz, 2H), 8.22 (s, 1H), 7.91 (d, $J = 8.6$ Hz, 2H), 7.85-7.83 (dd, $J = 8.5, 1.6$ Hz, 1H), 7.74 (d, $J = 8.2$ Hz, 2H), 7.67 (d, $J = 8.4$ Hz, 1H), 7.39 (d, $J = 8.1$ Hz, 2H), 2.77-2.73 (q, $J = 7.6$ Hz, 2H), 1.28 (t, $J = 7.6$ Hz, 3H).

Example 13




15

20 2-[4-(Benzo[1,3]dioxole-5-carbonyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 4 substituting benzo[1,3]dioxole-5-carbaldehyde for 4-chloro-benzaldehyde in Step A. TLC (silica, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2): $R_f = 0.28$. HPLC (Method A): $R_t = 7.08$. MS (ESI+): mass calculated for $\text{C}_{22}\text{H}_{15}\text{N}_3\text{O}_4$, 385.1; m/z found, 386.1 $[\text{M}+\text{H}]^+$. ^1H NMR (500 MHz, CD_3OD): δ 8.26 (d, $J = 8.4$ Hz, 2H), 8.23 (br s, 1H), 7.90 (d, $J = 8.4$ Hz, 2H), 7.86-7.84 (dd, $J = 8.5, 1.6$

Hz, 1H), 7.69 (d, $J = 8.3$ Hz, 1H), 7.42-7.40 (dd, $J = 8.1, 1.7$ Hz, 1H), 7.35 (d, $J = 1.6$ Hz, 1H), 6.96 (d, $J = 8.1$ Hz, 1H), 6.1 (s, 2H).


Example 14



5 2-[4-(2,3-Dihydro-benzo[1,4]dioxine-6-carbonyl)-phenyl]-1H-benzimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 4 substituting 2,3-dihydro-benzo[1,4]dioxine-6-carbaldehyde for 4-chloro-benzaldehyde in Step A. TLC (silica, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2): $R_f = 0.30$. HPLC (Method A): $R_t = 7.29$. MS (ESI+): mass calculated for $\text{C}_{23}\text{H}_{17}\text{N}_3\text{O}_4$, 399.1; m/z found, 400.1 $[\text{M}+\text{H}]^+$. ^1H NMR (500 MHz, CD_3OD): δ 8.23 (d, $J = 8.5$ Hz, 2H), 8.21 (s, 1H), 7.87 (d, $J = 8.5$ Hz, 2H), 7.85-7.83 (dd, $J = 8.5, 1.6$ Hz, 1H), 7.67 (br d, $J = 8.4$ Hz, 1H), 7.35-7.33 (m, 2H), 6.96 (d, $J = 8.9$ Hz, 1H), 4.35-4.33 (m, 2H), 4.30-4.28 (m, 2H).


15 Example 15



2-[4-(Quinoline-3-carbonyl)-phenyl]-1H-benzimidazole-5-carboxylic acid amide
The title compound was prepared as described in Example 4 substituting quinoline-3-carbaldehyde for 4-chloro-benzaldehyde in Step A. TLC (silica, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2): $R_f = 0.20$. HPLC (Method A): $R_t = 6.96$. MS (ESI+): mass calculated for $\text{C}_{24}\text{H}_{16}\text{N}_4\text{O}_2$, 392.1; m/z found, 393.1 $[\text{M}+\text{H}]^+$. ^1H NMR (500 MHz, $\text{CD}_3\text{OD}/\text{DMSO}-d_6$): δ 9.28 (d, $J = 2.2$ Hz, 1H), 8.80 (d, $J = 2.1$ Hz, 1H), 8.41 (d, $J = 8.1$ Hz, 2H), 8.24 (br s, 1H), 8.17-8.16 (dd, $J = 6.1, 0.8$ Hz, 2H), 8.09 (d, $J = 8.3$ Hz, 2H), 7.97-7.94 (m, 1H), 7.87-

7.85 (dd, $J = 8.4, 1.2$ Hz, 1H), 7.74 (t, $J = 7.1$ Hz, 1H), 7.71 (br d, $J = 8.3$ Hz, 1H).


Example 16



5 2-[4-(Pyridine-4-carbonyl)-phenyl]-1H-benzimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 4 substituting pyridine-4-carbaldehyde for 4-chloro-benzaldehyde in Step A. TLC (silica, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2): $R_f = 0.25$. HPLC (Method A): $R_t = 6.22$. MS (ESI+): mass calculated for $\text{C}_{20}\text{H}_{14}\text{N}_4\text{O}_2$, 342.1; m/z found, 343.1 $[\text{M}+\text{H}]^+$. ^1H NMR (500 MHz, CD_3OD): δ 8.80 (d, $J = 6.0$ Hz, 2H), 8.29 (d, $J = 8.4$ Hz, 2H), 8.22 (br s, 1H), 8.01 (d, $J = 8.4$ Hz, 2H), 7.86 (br d, $J = 8.3$ Hz, 1H), 7.74 (d, $J = 6.0$ Hz, 2H), 7.68 (br s, 1H).


Example 17



15 2-(4-Cyclohexanecarbonyl-phenyl)-1H-benzimidazole-5-carboxylic acid amide


The title compound was prepared as described in Example 4 substituting cyclohexanecarbaldehyde for 4-chloro-benzaldehyde in Step A. TLC (silica, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2): $R_f = 0.29$. HPLC (Method A): $R_t = 7.50$. MS (ESI+): mass calculated for $\text{C}_{21}\text{H}_{21}\text{N}_3\text{O}_2$, 347.2, m/z found, 347.7 $[\text{M}+\text{H}]^+$. ^1H NMR (500 MHz, CD_3OD): δ 8.13 (d, $J = 8.5$ Hz, 2H), 8.12 (br s, 1H), 8.03 (d, $J = 8.6$ Hz, 2H), 7.75-7.73 (dd, $J = 8.5, 1.2$ Hz, 1H), 7.58 (br d, $J = 7.3$ Hz, 1H), 3.36-3.31 (m, 1H), 1.83-1.77 (m, 2H), 1.76-1.73 (m, 2H), 1.68-1.64 (m, 1H), 1.45-1.32 (m, 4H), 1.23-1.18 (m, 1H).

Example 18

2-[4-(4-Chloro-benzoyl)-phenyl]-1*H*-benzoimidazole-5-sulfonic acid amide

The title compound was prepared as described in Example 1 substituting 3,4-diamino-benzenesulfonamide for 3,4-diamino-benzamide and 4-(4-chloro-benzoyl)-benzaldehyde for 4-(2-phenyl-[1,3]dioxolan-2-yl)-benzaldehyde in Step C' (reaction mixture was heated to 60 °C). TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.32. HPLC (Method A): R_t = 8.03. MS (ESI⁺): mass calculated for C₂₀H₁₄ClN₃O₃S, 411.0; m/z found, 412.0 [M+H]⁺. ¹H NMR (500 MHz, DMSO-d₆): δ 13.48 (br s, 1H), 8.31 (d, *J* = 8.3 Hz, 2H), 8.16 (br s, 1H), 7.88 (d, *J* = 8.3 Hz, 2H), 7.76 (br s, 1H), 7.74 (d, *J* = 8.5 Hz, 2H), 7.73 (br s, 1H), 7.60 (d, *J* = 8.5 Hz, 2H), 7.25 (br s, 2H).


Example 19

2-[4-(Hydroxy-phenyl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

To a solution of 2-(4-benzoyl-phenyl)-1*H*-benzoimidazole-5-carboxylic acid amide (Example 3, 18 mg, 0.05 mmol) in anhydrous methanol (2.0 mL) was added sodium borohydride (2.0 mg, 0.05 mmol) in one portion. The reaction mixture was stirred under N₂ for 1 h. The solvent was removed under reduced pressure, and the residue was re-dissolved in 1:1 ethyl acetate/H₂O (40 mL). The solution was washed with H₂O (20 mL) then brine (20 mL) and dried (Na₂SO₄). Solvent was removed under reduced pressure, and purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 15 mg (83%) of the title compound. TLC (silica, 1%

methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.13. HPLC (Method A): R_t = 6.36. MS (ESI⁺): mass calculated for C₂₁H₁₇N₃O₂, 343.1; m/z found, 344.1 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD): δ 8.17 (br s, 1H), 8.07 (d, *J* = 8.4 Hz, 2H), 7.82-7.80 (dd, *J* = 8.4, 1.4 Hz, 1H), 7.63 (br d, *J* = 6.7 Hz, 1H), 7.58 (d, *J* = 8.2 Hz, 2H), 7.42-7.40 (dd, *J* = 8.5, 1.4 Hz, 2H), 7.32 (t, *J* = 7.5 Hz, 2H), 7.26-7.22 (m, 1H), 5.85 (s, 1H).


Example 20



2-{4-[(4-Chloro-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 19 from 2-[4-(4-chloro-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide (Example 4, 22 mg, 0.06 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 13 mg (60%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.14. HPLC (Method A): R_t = 7.02. MS (ESI⁺): mass calculated for C₂₁H₁₆ClN₃O₂, 377.1; m/z found, 378.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.17 (br s, 1H), 8.08 (d, *J* = 8.4 Hz, 2H), 7.81 (br d, *J* = 7.5 Hz, 1H), 7.64 (br s, 1H), 7.57 (d, *J* = 8.2 Hz, 2H), 7.40 (d, *J* = 8.4 Hz, 2H), 7.33 (d, *J* = 8.6 Hz, 2H), 5.85 (s, 1H).


Example 21



2-[4-(Hydroxy-p-tolyl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 19 from 2-[4-(4-methyl-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide (Example 5, 60 mg, 0.16 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 55 mg (91%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.2. HPLC (Method A): R_t = 6.89. MS (ESI⁺): mass calculated for C₂₂H₁₉N₃O₂, 357.1; m/z found, 358.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.21-8.11 (br m, 1H), 8.06 (d, *J* = 8.3 Hz, 2H), 7.80 (br s, 1H), 7.67 (br s, 1H), 7.56 (d, *J* = 8.2 Hz, 2H), 7.28 (d, *J* = 8.0 Hz, 2H), 7.15 (d, *J* = 7.9 Hz, 2H), 5.82 (s, 1H), 2.30 (s, 3H).


Example 22



2-{4-[Hydroxy-(4-methoxy-phenyl)-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 19 from 2-[4-(4-methoxy-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide (Example 6, 35 mg, 0.09 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 25 mg (71%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.13. HPLC (Method A): R_t = 6.57. MS (ESI⁺): mass calculated for C₂₂H₁₉N₃O₃, 373.1; m/z found, 374.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.10 (br s, 1H), 7.97 (d, *J* = 8.3 Hz, 2H), 7.71 (br d, *J* = 7.7 Hz, 1H), 7.53 (br s, 1H), 7.47 (d, *J* = 8.2 Hz, 2H), 7.20 (d, *J* = 8.7 Hz, 2H), 6.79 (d, *J* = 8.7 Hz, 2H), 5.71 (s, 1H), 3.66 (s, 3H).


Example 23



2-[4-(Hydroxy-naphthalen-2-yl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

- 5 The title compound was prepared as described in Example 19 from 2-[4-(naphthalene-2-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide (Example 7, 60 mg, 0.15 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 43 mg (72% of the title compound. TLC (silica, 1% methanol saturated with
- 10 ammonia/9% methanol/CH₂Cl₂): R_f = 0.21. HPLC (Method A): R_t = 7.18. MS (ESI⁺): mass calculated for C₂₅H₁₉N₃O₂, 393.1; m/z found, 394.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.18 (br s, 1H), 8.08 (d, *J* = 8.4 Hz, 2H), 7.92 (s, 1H), 7.84 (d, *J* = 8.9 Hz, 1H), 7.80 (d, *J* = 8.5 Hz, 3H), 7.63 (d, *J* = 8.3 Hz, 3H), 7.48-7.41 (m, 3H), 6.02 (s, 1H).

15 Example 24




2-[4-[(4-Chloro-3-trifluoromethyl-phenyl)-hydroxy-methyl]-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

- The title compound was prepared as described in Example 19 from 2-[4-(4-chloro-3-trifluoromethyl-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid
- 20 amide (Example 8, 69 mg, 0.15 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 60 mg (87%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.17. HPLC (Method A): R_t = 7.5. MS
- 25 (ESI⁻): mass calculated for C₂₂H₁₅ClF₃N₃O₂, 445.1; m/z found, 444.5 [M-H]⁻. ¹H

NMR (500 MHz, CD₃OD): δ 8.17 (br s, 1H), 8.10 (d, J = 8.4 Hz, 2H), 7.85 (d, J = 1.8 Hz, 1H), 7.81 (br d, J = 8.4 Hz, 1H), 7.64-7.62 (dd, J = 8.3, 1.9 Hz, 2H), 7.59-7.55 (m, 3H), 5.93 (s, 1H).


Example 25



2-{4-[(3-Bromo-4,5-dimethoxy-phenyl)-hydroxy-methyl]-phenyl}-1H-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 19 from 2-[4-(3-bromo-4,5-dimethoxy-benzoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide (Example 9, 60 mg, 0.12 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 37 mg (62%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.18. HPLC (Method A): R_t = 6.82. MS (ESI⁺): mass calculated for C₂₃H₂₀BrN₃O₄, 481.1; m/z found, 482.0/484.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.17 (br s, 1H), 8.07 (d, J = 8.4 Hz, 2H), 7.82-7.80 (dd, J = 8.5, 1.2 Hz, 1H), 7.63 (d, J = 7.6 Hz, 1H), 7.57 (d, J = 8.3 Hz, 2H), 7.20 (s, 1H), 7.11 (s, 1H), 6.14 (s, 1H), 3.82 (s, 3H), 3.80 (s, 3H).

Example 26




2-{4-[(3,4-Dichloro-phenyl)-hydroxy-methyl]-phenyl}-1H-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 19 from 2-[4-(3,4-dichloro-benzoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide (Example 10, 70 mg, 0.17 mmol). HPLC (Method A): R_t = 7.29. MS (ESI⁺):

mass calculated for $C_{21}H_{15}Cl_2N_3O_2$, 411.1; m/z found, 412.2 $[M+H]^+$. 1H NMR (500 MHz, DMSO- d_6): δ 13.58 (br s, 1H), 8.23 (d, J = 8.2 Hz, 2H), 8.16 (br s, 1H), 8.01 (br s, 1H), 7.77 (dd, J = 8.1 Hz, 1H), 7.68 (d, J = 1.8 Hz, 1H), 7.59 (d, J = 8.3 Hz, 2H), 7.57 (d, J = 8.3 Hz, 2H), 7.41-7.39 (dd, J = 8.4, 1.8 Hz, 1H),
 5 7.24 (br s, 1H), 6.36 (d, J = 4.1 Hz, 1H), 5.83 (d, J = 3.8 Hz, 1H).


Example 27



2-{4-[(3,4-Dimethyl-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide

- 10 The title compound was prepared as described in Example 19 from 2-[4-(3,4-dimethyl-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide (Example 11, 60 mg, 0.16 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2) afforded 50.2 mg (84%) of the title compound. TLC (silica, 1% methanol saturated with
 15 ammonia/9% methanol/ CH_2Cl_2): R_f = 0.13. HPLC (Method A): R_t = 7.09. MS (ESI $^+$): mass calculated for $C_{23}H_{21}N_3O_2$, 371.2; m/z found, 372.2 $[M+H]^+$. 1H NMR (500 MHz, CD_3OD): δ 8.17 (br s, 1H), 8.05 (d, J = 8.4 Hz, 2H), 7.81-7.79 (dd, J = 8.4, 1.4 Hz, 1H), 7.62 (br d, J = 7.6 Hz, 1H), 7.56 (d, J = 8.1 Hz, 2H), 7.15 (s, 1H), 7.10-7.06 (m, 2H), 5.78 (s, 1H), 2.23 (s, 3H), 2.22 (s, 3H).

20 Example 28




2-{4-[(4-Ethyl-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide

- The title compound was prepared as described in Example 19 from 2-[4-(4-ethyl-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide (Example
 25

12, 60 mg, 0.16 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 52 mg (87%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.17. HPLC (Method A): R_t = 7.17. MS (ESI+): mass calculated for C₂₃H₂₁N₃O₂, 371.2; m/z found, 372.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.17 (br s, 1H), 8.06 (d, *J* = 8.4 Hz, 2H), 7.81-7.79 (dd, *J* = 8.5, 1.6 Hz, 1H), 7.62 (br d, *J* = 8.3 Hz, 1H), 7.56 (d, *J* = 8.1 Hz, 2H), 7.29 (d, *J* = 8.1 Hz, 2H), 7.16 (d, *J* = 8.2 Hz, 2H), 5.82 (s, 1H), 2.62-2.58 (q, *J* = 7.6 Hz, 2H), 1.19 (t, *J* = 7.6 Hz, 3H).


10 Example 29



2-[4-(Benzo[1,3]dioxol-5-yl-hydroxy-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 19 from 2-[4-(benzo[1,3]dioxole-5-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide (Example 13, 40 mg, 0.1 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 29 mg (71%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.16. HPLC (Method A): R_t = 6.78. MS (ESI+): mass calculated for C₂₂H₁₇N₃O₄, 387.1; m/z found, 388.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.17 (br s, 1H), 8.06 (d, *J* = 8.4 Hz, 2H), 7.82-7.80 (dd, *J* = 8.5, 1.6 Hz, 1H), 7.63 (d, *J* = 8.5 Hz, 1H), 7.56 (d, *J* = 8.2 Hz, 2H), 6.89-6.87 (dd, *J* = 8.1, 1.6 Hz, 1H), 6.86 (d, *J* = 1.6 Hz, 1H), 6.77 (d, *J* = 8.0 Hz, 1H), 5.91-5.89 (m, 2H), 5.77 (s, 1H).


Example 30



2-[4-[(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-hydroxy-methyl]-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

- 5 The title compound was prepared as described in Example 19 from 2-[4-(2,3-dihydro-benzo[1,4]dioxin-6-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide (Example 14, 60 mg, 0.15 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 46.6 mg (78%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.16. HPLC (Method A): R_t = 6.74. MS (ESI⁺): mass calculated for C₂₃H₁₉N₃O₄, 401.1; m/z found, 402.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.17 (br s, 1H), 8.06 (d, *J* = 8.3 Hz, 2H), 7.82-7.80 (dd, *J* = 8.4, 1.4 Hz, 1H), 7.63 (br d, *J* = 8.0 Hz, 1H), 7.55 (d, *J* = 8.3 Hz, 2H), 6.86 (d, *J* = 1.9 Hz, 1H), 6.84-6.82 (dd, *J* = 8.3, 1.9 Hz, 1H), 6.77 (d, *J* = 8.3 Hz, 1H), 5.74 (s, 1H), 4.19 (s, 4H).

Example 31




2-[4-(Hydroxy-quinolin-3-yl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

- 20 The title compound was prepared as described in Example 19 from 2-[4-(quinoline-3-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide (Example 15, 40 mg, 0.1 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 13.9 mg, (35%) of the title compound. HPLC (Method A): R_t = 6.04. MS (ESI⁺): mass calculated for C₂₄H₁₈N₄O₂, 394.1; m/z found, 395.1 [M+H]⁺. ¹H NMR (500

MHz, CD₃OD): δ 8.78 (d, J = 2.1 Hz, 1H), 8.26 (d, J = 1.0 Hz, 1H), 8.25 (br s, 1H), 8.02 (d, J = 8.4 Hz, 2H), 7.90 (d, J = 8.5 Hz, 1H), 7.84 (d, J = 8.2 Hz, 1H), 7.71 (d, J = 8.3 Hz, 1H), 7.66-7.63 (m, 1H), 7.58 (d, J = 8.3 Hz, 2H), 7.52 (br s, 1H), 7.51-7.49 (m, 1H), 6.03 (s, 1H).


5 Example 32



2-[4-(Hydroxy-pyridin-4-yl-methyl)-phenyl]-1*H*-benzimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 19 from 2-[4-(pyridine-4-carbonyl)-phenyl]-1*H*-benzimidazole-5-carboxylic acid amide (Example 16, 15 mg, 0.04 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 10.2 mg (68%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.09. HPLC (Method A): R_t = 5.64. MS (ESI⁺): mass calculated for C₂₀H₁₆N₄O₂, 344.1; m/z found, 345.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.39 (d, J = 6.2 Hz, 2H), 8.12 (br s, 1H), 8.00 (d, J = 8.3 Hz, 2H), 7.75 (br s, 1H), 7.51 (d, J = 8.3 Hz, 2H), 7.42 (d, J = 6.0 Hz, 2H), 5.79 (s, 1H).

Example 33




2-[4-(Cyclohexyl-hydroxy-methyl)-phenyl]-1*H*-benzimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 19 from 2-(4-cyclohexanecarbonyl-phenyl)-1*H*-benzimidazole-5-carboxylic acid amide (Example 17, 90 mg, 0.26 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 31 mg

(34%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.2. MS (ESI+): mass calculated for C₂₁H₂₃N₃O₂, 349.2; m/z found, 350.3 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.18 (br s, 1H), 8.07 (d, *J* = 8.3 Hz, 2H), 7.81 (d, *J* = 8.3 Hz, 1H), 7.63 (br s, 1H), 7.49 (d, *J* = 8.3 Hz, 2H), 4.40 (d, *J* = 7.0 Hz, 1H), 1.99 (d, *J* = 13.1 Hz, 1H), 1.77 (d, *J* = 12.9 Hz, 1H), 1.69-1.60 (m, 3H), 1.41 (d, *J* = 12.9 Hz, 1H), 1.28-1.01 (m, 5H).


Example 34



10 2-[4-(Methoxy-phenyl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

To a solution of 2-[4-(hydroxy-phenyl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide (Example 19, 8.7 mg, 0.02 mmol) in chloroform (1.0 mL) was added concentrated HCl (0.1 mL). The reaction mixture was stirred at RT for 2 h. Organics were removed under reduced pressure, and purification using preparative TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 4.2 mg (47%) of the title compound. HPLC (Method A): R_t = 6.97. MS (ESI+): mass calculated for C₂₂H₁₉N₃O₂, 357.1; m/z found, 358.2 [M+H]⁺. ¹H NMR (400 MHz, CD₃OD): δ 8.18 (br s, 1H), 8.08 (d, *J* = 8.2 Hz, 2H), 7.82 (br d, *J* = 8.0 Hz, 1H), 7.64 (br s, 1H), 7.56 (d, *J* = 8.3 Hz, 2H), 7.40 (d, *J* = 8.0 Hz, 2H), 7.35 (t, *J* = 7.5 Hz, 2H), 7.28-7.25 (m, 1H), 5.39 (s, 1H), 3.40 (s, 3H).


Example 35



25 2-[4-(4-Chloro-benzyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

To a solution of 2-{4-[(4-chloro-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide (Example 20, 50 mg, 0.13 mmol) in TFA (5.0 mL) was added sodium borohydride (211 mg, 4.2 equiv), and the reaction mixture was stirred at RT for 16 h. Water (5.0 mL) was added to the mixture, which was then adjusted to pH 9 with 1 N NaOH. The precipitate was collected by filtration and washed with H₂O (20 mL). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 39 mg (81%) of the title compound. HPLC (Method A): *R*_t = 7.64. MS (ESI⁺): mass calculated for C₂₁H₁₆ClN₃O, 361.1; *m/z* found, 362.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.23 (d, *J* = 1.4 Hz, 1H), 8.06 (d, *J* = 8.2 Hz, 2H), 7.94-7.92 (dd, *J* = 8.5, 1.6 Hz, 1H), 7.74 (d, *J* = 8.5 Hz, 1H), 7.48 (d, *J* = 8.2 Hz, 2H), 7.31 (d, *J* = 8.4 Hz, 2H), 7.25 (d, *J* = 8.4 Hz, 2H), 4.09 (s, 2H).


Example 36



2-(4-Naphthalen-2-ylmethyl-phenyl)-1*H*-benzoimidazole-5-carboxylic acid amide


The title compound was prepared as described in Example 35 from 2-[4-(hydroxy-naphthalen-2-yl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide (Example 23, 20 mg, 0.05 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 19 mg (100 %) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): *R*_f = 0.33. HPLC (Method A): *R*_t = 7.80. MS (ESI⁺): mass calculated for C₂₅H₁₉N₃O, 377.2; *m/z* found, 378.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.17 (dd, *J* = 1.5, 0.5 Hz, 1H), 7.97 (d, *J* = 8.4 Hz, 2H), 7.93-7.91 (dd, *J* = 8.5, 1.5 Hz, 1H), 7.71-7.67 (m, 4H), 7.63 (s, 1H), 7.49 (d, *J* = 8.4 Hz, 2H), 7.37-7.37 (m, 2H), 7.27-7.25 (dd, *J* = 8.4, 1.6 Hz, 1H), 4.18 (s, 2H).

Example 37

2-[4-(3,4-Dimethyl-benzyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 35 from 2-{4-[(3,4-dimethyl-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide (Example 27, 14 mg, 0.03 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 11.1 mg (83%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.39. HPLC (Method A): R_t = 8.11. MS (ESI⁺): mass calculated for C₂₃H₂₁N₃O, 355.2; m/z found, 356.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.17 (s, 1H), 8.04 (d, *J* = 8.2 Hz, 2H), 7.81 (br d, *J* = 8.2 Hz, 1H), 7.63 (br s, 1H), 7.40 (d, *J* = 8.2 Hz, 2H), 7.05 (d, *J* = 7.7 Hz, 1H), 7.02 (s, 1H), 6.96 (d, *J* = 7.6 Hz, 1H), 3.97 (s, 2H), 2.22 (d, *J* = 4.1 Hz, 6H).


Example 38

2-[4-(4-Ethyl-benzyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 35 from 2-{4-[(4-ethyl-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide (Example 28, 26.5 mg, 0.07 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 19 mg (76%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.41. HPLC (Method A): R_t = 7.84. MS (ESI⁺): mass calculated for C₂₃H₂₁N₃O, 355.2; m/z found, 356.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.16 (d, *J* = 1.5 Hz, 1H), 7.94 (d, *J* = 8.4 Hz, 2H), 7.89 (dd, *J* = 8.6, 1.6 Hz, 1H), 7.67 (d, *J* = 8.5 Hz, 1H), 7.41 (d, *J* =

8.4 Hz, 2H), 7.05-7.04 (m, 4H), 3.96 (s, 2H), 2.53-2.48 (q, $J = 7.6$ Hz, 2H), 1.10 (t, $J = 7.6$ Hz, 3H).


Example 39



5 2-[4-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 35 from 2-{4-[(2,3-dihydro-benzo[1,4]dioxin-6-yl)-hydroxy-methyl]-phenyl}-1H-benzoimidazole-5-carboxylic acid amide (Example 30, 15.3 mg, 0.04 mmol). Purification by
 10 chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2) afforded 12.1 mg (83%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2): $R_f = 0.30$. HPLC (Method A): $R_t = 7.19$. MS (ESI+): mass calculated for $\text{C}_{23}\text{H}_{19}\text{N}_3\text{O}_3$, 385.1; m/z found, 386.1 $[\text{M}+\text{H}]^+$. ^1H NMR (500 MHz, CD_3OD): δ
 15 8.10 (d, $J = 1.4$ Hz, 1H), 7.92 (d, $J = 8.3$ Hz, 2H), 7.79-7.77 (dd, $J = 8.5, 1.6$ Hz, 1H), 7.59 (d, $J = 8.5$ Hz, 1H), 7.32 (d, $J = 8.3$ Hz, 2H), 6.65 (d, $J = 8.9$ Hz, 1H), 6.59-6.57 (m, 2H), 4.09 (s, 1H), 3.84 (s, 2H).

Example 40




20 2-(4-Cyclohexylmethyl-phenyl)-1H-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 35 from 2-[4-(cyclohexyl-hydroxy-methyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide (Example 33, 11.4 mg, 0.03 mmol). Product was isolated as a TFA salt (7.3 mg, 50%). HPLC (Method A): $R_t = 8.46$. MS (ESI+): mass calculated for
 25 $\text{C}_{21}\text{H}_{23}\text{N}_3\text{O}$, 333.2, m/z found, 446.3 $[\text{M}+\text{H}]^+ + \text{TFA}$. ^1H NMR (500 MHz,

CD₃OD): δ 8.19 (d, J = 1.5 Hz, 1H), 8.08 (d, J = 8.4 Hz, 2H), 7.92-7.89 (d, J = 8.6, 1.5 Hz, 1H), 7.69 (d, J = 8.5 Hz, 1H), 7.57 (d, J = 8.4 Hz, 2H), 5.69 (d, J = 7.9 Hz, 1H), 1.96-1.91 (m, 1H), 1.87-1.82 (m, 1H), 1.73-1.69 (m, 1H), 1.66-1.59 (m, 2H), 1.35-1.32 (m, 1H), 1.20-0.95 (m, 6H).

5 Example 41



2-{4-[1-(4-Chloro-phenyl)-vinyl]-phenyl}-1H-benzoimidazole-5-carboxylic acid amide

A. 1-(4-Chloro-phenyl)-1-(4-[1,3]dioxan-2-yl-phenyl)-ethanol. To a solution of 10 1-(4-chloro-phenyl)-ethanone (582 mg, 3.7 mmol) in anhydrous THF (25 mL), cooled to -78 °C, was added 4-(1,3-dioxan-2-yl)phenylmagnesium bromide (16 mL, 0.25 M in THF) dropwise. The reaction mixture was stirred 1 h at -78 °C then was quenched with saturated aqueous NH₄Cl (50 mL). The resulting mixture was extracted with Et₂O (2 X 100 mL), and the combined extracts were 15 washed with H₂O (100 mL) then brine (100 mL), and dried (MgSO₄). Solvent was removed under reduced pressure. Purification of the residue by chromatography (silica gel, 50% ethyl acetate/hexanes) afforded 627 mg (52%) of the title compound. TLC (silica, 50% ethyl acetate/hexanes): R_f = 0.42. HPLC (Method A): R_t = 10.16. ¹H NMR (500 MHz, CD₃OD): δ 7.41 (d, J = 8.3 Hz, 2H); 7.35 (d, J = 8.5 Hz, 2H), 7.27 (d, J = 8.7 Hz, 2H), 7.21 (d, J = 8.7 Hz, 2H), 5.46 (s, 1H), 4.24-4.20 (m, 2H), 3.98-3.92 (m, 2H), 2.94 (s, 1H), 2.23-2.14 (m, 1H), 1.84 (s, 3H), 1.43-1.39 (m, 1H).


B. 4-[1-(4-Chloro-phenyl)-vinyl]-benzaldehyde. This compound was prepared as described in Example 3 substituting 1-(4-chloro-phenyl)-1-(4-[1,3]dioxan-2-yl-phenyl)-ethanol (150 mg, 0.47 mmol) for 4-(2-phenyl-[1,3]dioxolan-2-yl)- 25 benzaldehyde in Step A. The title compound (100 mg, 88%) was used without purification in the next reaction. TLC (silica, 50% ethyl acetate/hexanes): R_f = 0.66. HPLC (Method A): R_t = 10.65. ¹H NMR (500 MHz, CD₃OD): δ 10.02 (s,

1H), 7.86 (d, $J = 8.2$ Hz, 2H), 7.47 (d, $J = 8.2$ Hz, 2H), 7.32 (d, $J = 8.6$ Hz, 2H), 7.24 (d, $J = 8.6$ Hz, 2H), 5.58 (s, 1H), 5.57 (s, 1H).

C. 2-{4-[1-(4-Chloro-phenyl)-vinyl]-phenyl}-1H-benzoimidazole-5-carboxylic acid amide. This compound was prepared as described in Example 1

- 5 substituting 4-[1-(4-chloro-phenyl)-vinyl]-benzaldehyde (100 mg, 0.4 mmol) for 4-(2-phenyl-[1,3]dioxolan-2-yl)-benzaldehyde in Step C. Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2) afforded the title compound (60 mg, 39%).
- TLC (silica, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2): $R_f =$
- 10 0.29. HPLC (Method A): $R_t = 7.89$. MS (ESI+): mass calculated for $\text{C}_{22}\text{H}_{16}\text{ClN}_3\text{O}$, 373.1, m/z found, 373.6 $[\text{M}+\text{H}]^+$. ^1H NMR (500 MHz, CD_3OD): δ 8.10 (br s, 1H), 8.02 (d, $J = 8.5$ Hz, 2H), 7.74 (br d, $J = 8.5$ Hz, 1H), 7.58 (br s, 1H), 7.42 (d, $J = 8.5$ Hz, 2H), 7.29 (d, $J = 8.7$ Hz, 2H), 7.24 (d, $J = 8.7$ Hz, 2H), 5.53 (s, 1H), 5.48 (s, 1H).

15 Example 42




2-{4-[1-(4-Chloro-phenyl)-ethyl]-phenyl}-1H-benzoimidazole-5-carboxylic acid amide

- A flask containing a solution of 2-{4-[1-(4-chloro-phenyl)-vinyl]-phenyl}-1H-benzoimidazole-5-carboxylic acid amide (Example 41, 30 mg, 0.08 mmol) in
- 20 1:1 ethanol/ethyl acetate (6.0 mL) was charged with N_2 and evacuated (3X). Palladium on carbon (10 wt %) was added to the solution, and the flask was charged with H_2 and evacuated (3X), and then maintained at ~ 1 atm H_2 for 2.5 h. The flask was evacuated and then charged with N_2 . The reaction
- 25 mixture was filtered through a pad of Celite[®], which was washed with ethanol (50 mL), ethyl acetate (50 mL) and then methanol (2 X 50 mL). The filtrate was concentrated under reduced pressure. Purification of the residue by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2) afforded the title compound (21 mg, 68%).

TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.35. MS (ESI⁺): mass calculated for C₂₂H₁₈ClN₃O, 375.1, m/z found, 376.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.16 (br s, 1H), 8.04 (d, J = 8.4 Hz, 2H), 7.81 (d, J = 8.3 Hz, 1H), 7.62 (br s, 1H), 7.43 (d, J = 8.3 Hz, 2H), 7.30-7.26 (m, 4H), 4.27-4.24 (m, 1H), 1.67 (d, J = 7.2 Hz, 3H).


Example 43



2-{4-[(4-Chloro-phenyl)-piperazin-1-yl-methyl]-phenyl}-1*H*-benzimidazole-5-carboxylic acid amide

- 10 To a suspension of 2-{4-[(4-chloro-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzimidazole-5-carboxylic acid amide (Example 20, 20.0 mg, 0.05 mmol) in CH₂Cl₂ (10 mL) was added thionyl chloride (0.04 mL, 0.06 mmol), and the mixture was stirred at RT for 1 h. Solvent was removed under reduced pressure, and the residue was dried under high vacuum. The crude product
- 15 was dissolved in acetonitrile (10 mL). Piperazine (21 mg, 0.24 mmol) was added, and the mixture was heated to reflux for 12 h. Solvent was removed under reduced pressure, and purification of the residue by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 17 mg (77%) of the title compound. HPLC (Method A): R_t = 6.44. MS
- 20 (ESI⁻): mass calculated for C₂₅H₂₄ClN₅O, 445.2; m/z found, 444.6 [M-H]⁻. ¹H NMR (500 MHz, CD₃OD): δ 8.17 (br s, 1H), 8.09 (d, J = 8.4 Hz, 2H), 7.82-7.80 (dd, J = 8.5, 1.5 Hz, 1H), 7.66 (d, J = 8.4 Hz, 2H), 7.63 (br s, 1H), 7.50 (d, J = 8.5 Hz, 2H), 7.35 (d, J = 8.5 Hz, 2H), 4.56 (s, 1H), 3.31-3.27 (m, 8H).


Example 44



2-(4-((4-Chloro-phenyl)-[methyl-(2-methylamino-ethyl)-amino]-methyl)-phenyl)-1H-benzoimidazole-5-carboxylic acid amide

- 5 The title compound was prepared as described in Example 43 substituting *N,N'*-dimethyl-ethane-1,2-diamine for piperazine. HPLC (Method A): $R_t = 6.73$. MS (ESI⁺): mass calculated for $C_{25}H_{26}ClN_5O$, 447.2; m/z found, 448.1 $[M+H]^+$. ¹H NMR (500 MHz, CD₃OD): δ 8.07 (d, $J = 1.1$ Hz, 1H), 7.96 (d, $J = 8.3$ Hz, 2H), 7.72-7.70 (dd, $J = 8.5, 1.5$ Hz, 1H), 7.54 (d, $J = 7.9$ Hz, 2H), 7.52 (s, 1H), 7.38 (d, $J = 8.5$ Hz, 2H), 7.20 (d, $J = 8.5$ Hz, 2H), 4.40 (s, 1H), 2.63 (t, $J = 6.5$ Hz, 2H), 2.43 (t, $J = 6.4$ Hz, 2H), 2.26 (s, 3H), 2.10 (s, 3H).
- 10

Example 45



- 2-[4-(Methyl-phenyl-amino)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide
- 15
- A. (4-Bromo-phenyl)-methyl-phenyl-amine. To a cooled solution (0 °C) of methyl-diphenyl-amine (1.17 g, 6.4 mmol) in anhydrous CH₂Cl₂ (20 mL) was slowly added *N*-bromosuccinimide (1.15 g, 6.4 mmol) dissolved in CH₂Cl₂ (20 mL). The reaction mixture was stirred for 2 h at 0 °C and then refrigerated overnight. Solvent was removed under reduced pressure, and the residue was purified by chromatography (silica gel, 10% ethyl acetate/hexanes) to afford 1.38 g (82%) of the title compound. ¹H NMR (500 MHz, CDCl₃): δ 7.32 (d, $J = 9.0$ Hz, 2H), 7.29 (d, $J = 8.6$ Hz, 2H), 7.06-7.04 (dd, $J = 8.7, 1.1$ Hz, 2H), 7.03-7.02 (m, 1H), 6.83 (d, $J = 8.9$ Hz, 2H), 3.28 (s, 3H).
- 20

B. 4-(Methyl-phenyl-amino)-benzaldehyde. This compound was prepared as described in Example 1 substituting (4-bromo-phenyl)-methyl-phenyl-amine (500 mg, 1.19 mmol) for 2-(4-bromo-phenyl)-2-phenyl-[1,3]dioxolane in Step B. Purification by chromatography (silica gel, 10% ethyl acetate/hexanes) afforded the title compound, 381 mg (94%). ¹H NMR (500 MHz, CDCl₃): δ 9.76 (s, 1H), 7.69 (d, *J* = 8.9 Hz, 2H), 7.43 (t, *J* = 7.8 Hz, 2H), 7.28 (d, *J* = 7.4 Hz, 1H), 7.24-7.22 (dd, *J* = 8.4, 1.2 Hz, 2H), 6.78 (d, *J* = 8.9 Hz, 2H), 3.39 (s, 3H).


C. 2-[4-(Methyl-phenyl-amino)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid.

This compound was prepared as described in Example 1 using 4-(methyl-phenyl-amino)-benzaldehyde (380 mg, 1.8 mmol) and 3,4-diamino-benzoic acid (273 mg, 1.8 mmol) in Step C. Crude product (528 mg, 85%) was used without further purification. HPLC (Method A): *R*_t = 7.38. MS (ESI): mass calculated for C₂₁H₁₇N₃O₂, 343.1; *m/z* found, 344.1 [M+H]⁺, 342.1, [M-H]⁻.

D. 2-[4-(Methyl-phenyl-amino)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid

amide. This compound was prepared as described in Example 2 using 2-[4-(methyl-phenyl-amino)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid (500 mg, 1.4 mmol) in Step D. Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 329 mg (66%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): *R*_f = 0.35. HPLC (Method A): *R*_t = 7.07. MS (ESI): mass calculated for C₂₁H₁₈N₄O, 342.1, *m/z* found, 343.2 [M+H]⁺, 341.2, [M-H]⁻. ¹H NMR (400 MHz, CD₃OD): δ 8.01 (s, 1H), 7.82 (d, *J* = 8.9 Hz, 2H), 7.68-7.65 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.47 (br d, *J* = 8.4 Hz, 1H), 7.31 (t, *J* = 7.9 Hz, 2H), 7.14-7.12 (dd, *J* = 8.6, 1.2 Hz, 2H), 7.09 (d, *J* = 7.4 Hz, 1H), 6.83 (d, *J* = 8.9 Hz, 2H), 3.27 (s, 3H).

Example 46



2-(4-Benzylsulfamoyl-phenyl)-1*H*-benzoimidazole-5-carboxylic acid amide

A. *N*-Benzyl-4-formyl-benzenesulfonamide. To a solution of 4-


formylbenzenesulfonyl chloride (200 mg, 0.978 mmol) and benzylamine (105

mg, 0.978 mmol) in anhydrous CH_2Cl_2 (3.3 mL) was added triethylamine (198 mg, 1.96 mmol) dropwise. The mixture was stirred at RT for 17 h, and then diluted with saturated aqueous NaHCO_3 . The aqueous layer was extracted with ethyl acetate (X3), and the combined organic extracts were washed with brine and dried (MgSO_4). The solvent was removed under reduced pressure, and the residue was purified by chromatography (silica gel, 20% EtOAc/hexanes) to provide 197 mg (73%) of the title compound as a white solid. HPLC (Method C): R_t = 6.01. MS (ESI): mass calculated for $\text{C}_{14}\text{H}_{13}\text{NO}_3\text{S}$, 275.1; m/z found, 274.2 $[\text{M}-\text{H}]^-$. ^1H NMR (400 MHz, CDCl_3): δ 10.1 (s, 1H), 8.05-8.00 (m, 4H), 7.30-7.28 (m, 3H), 7.21 (dd, J = 2.2, 9.6 Hz, 2H), 5.15 (bt, J = 6.0 Hz, 1H), 4.23 (d, J = 6.1 Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3): δ 191.3, 145.7, 139.2, 136.2, 130.6, 129.2, 128.5, 128.3, 128.2, 47.8.

B. 2-(4-Benzylsulfamoyl-phenyl)-1H-benzoimidazole-5-carboxylic acid amide.

A solution of *N*-benzyl-4-formyl-benzenesulfonamide (137 mg, 0.497 mmol), 3,4-diamino-benzamide (75 mg, 0.497 mmol), and sodium metabisulfite (123 mg, 0.646 mmol) in DMF (5 mL) was heated at 60 °C for 14.5 h. After cooling to RT, the reaction mixture was poured into ice-cold saturated aqueous NH_4Cl (25 mL), and the precipitate was collected by vacuum filtration. Purification by chromatography (silica gel, 10% methanol saturated with NH_3 /30% THF/ 60% CH_2Cl_2) afforded a purple solid, which was triturated with CH_2Cl_2 to provide 36 mg (18%) of the title compound as a gray powder. HPLC (Method C): R_t = 4.55. MS (ESI): mass calculated for $\text{C}_{21}\text{H}_{18}\text{N}_4\text{O}_3\text{S}$, 406.1; m/z found, 407.3 $[\text{M}+\text{H}]^+$. ^1H NMR (400 MHz, CD_3OD): δ 8.21 (d, J = 8.6 Hz, 3H), 7.96 (d, J = 8.6 Hz, 2H), 7.85 (dd, J = 1.6, 8.5 Hz, 1H), 7.67 (d, J = 8.5 Hz, 1H), 7.22-7.18 (m, 5H), 4.13 (s, 2H).

Example 47




2-[4-(4-Methyl-benzylsulfamoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide

A. 4-Formyl-*N*-(4-methyl-benzyl)-benzenesulfonamide. This compound was prepared as described in Example 46 substituting 4-methylbenzylamine (119 mg, 0.978 mmol) for benzylamine in Step A. The title compound was obtained as a white solid (162 mg, 57%).

- 5 B. 2-[4-(4-Methyl-benzylsulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide. This compound was prepared as described in Example 46 substituting 4-formyl-*N*-(4-methyl-benzyl)-benzenesulfonamide (144 mg, 0.497 mmol) for *N*-benzyl-4-formyl-benzenesulfonamide in Step B. The title compound was obtained as a purple solid (38 mg, 18%). HPLC (Method C): $R_t = 4.73$. MS (ESI): mass calculated for $C_{22}H_{20}N_4O_3S$, 420.1; m/z found, 421.4 $[M+H]^+$. 1H NMR (400 MHz, CD_3OD): δ 8.20 (d, $J = 8.4$ Hz, 3H), 7.95 (d, $J = 8.4$ Hz, 2H), 7.85 (d, $J = 8.3$ Hz, 1H), 7.66 (bs, 1H), 7.07 (d, $J = 8.0$ Hz, 2H), 7.01 (d, $J = 7.9$ Hz, 2H), 4.08 (s, 2H).
- 10

Example 48




2-[4-(4-Methoxy-benzylsulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

- A. 4-Formyl-*N*-(4-methoxy-benzyl)-benzenesulfonamide. This compound was prepared as described in Example 46 Step A, substituting 4-methoxybenzylamine (335 mg, 2.44 mmol) for benzylamine. The title compound was obtained as a white solid (686 mg, 92%).
- 20

- B. 2-[4-(4-Methoxy-benzylsulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide. This compound was prepared as described in Example 46 Step B, substituting 4-formyl-*N*-(4-methoxy-benzyl)-benzenesulfonamide (202 mg, 0.66 mmol) for *N*-benzyl-4-formyl-benzenesulfonamide. The reaction was run at 90 °C instead of 60 °C. The title compound was obtained as a yellow powder (90 mg, 31%). HPLC (Method C): $R_t = 4.48$. MS (ESI): mass calculated for $C_{22}H_{20}N_4O_4S$, 436.1; m/z found, 437.1 $[M+H]^+$. 1H NMR (400 MHz, C_2D_6SO): δ 8.37 (d, $J = 8.5$ Hz, 2H), 8.21 (m, 2H), 7.97 (d, $J = 8.5$ Hz, 2H), 7.84 (d, 9.1 Hz,
- 25

1H), 7.17 (d, J = 8.7 Hz, 1H), 6.84 (d, J = 8.7 Hz, 2H), 3.69 (s, 2H), 3.41 (s, 3H).

Example 49




- 5 2-[4-(4-Chloro-benzylsulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

A. *N*-(4-Chloro-benzyl)-4-formyl-benzenesulfonamide. This compound was prepared as described in Example 46 substituting 4-chlorobenzylamine (138 mg, 0.978 mmol) for benzylamine in Step A. The title compound was obtained as a white solid (236 mg, 78%).

10 B. 2-[4-(4-Chloro-benzylsulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide. This compound was prepared as described in Example 46 substituting *N*-(4-chloro-benzyl)-4-formyl-benzenesulfonamide (155 mg, 0.50 mmol) for *N*-benzyl-4-formyl-benzenesulfonamide in Step B. The title compound was obtained as a brown powder (30 mg, 14%). HPLC (Method C): R_t = 4.78. MS (ESI): mass calculated for $C_{21}H_{17}ClN_4O_3S$, 440.1; m/z found, 441.3 $[M+H]^+$. 1H NMR (400 MHz, CD_3OD): δ 8.13-8.11 (m, 3H), 7.86 (d, J = 8.5 Hz, 2H), 7.75 (dd, J = 1.6, 8.5 Hz, 1H), 7.58 (d, J = 8.5 Hz, 1H), 7.10 (s, 4H), 4.01 (s, 2H).

20 Example 50



2-[4-(3,4-Dichloro-benzylsulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide


A. *N*-(3,4-Dichloro-benzyl)-4-formyl-benzenesulfonamide. This compound was prepared as described in Example 46 substituting 3,4-dichlorobenzylamine

(172 mg, 0.978 mmol) for benzylamine in Step A. The title compound was obtained as a white solid, 216 mg (64%).

B. 2-[4-(3,4-Dichloro-benzylsulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide. This compound was prepared as described in Example 46

- 5 substituting *N*-(3,4-dichloro-benzyl)-4-formyl-benzenesulfonamide (171 mg, 0.497 mmol) for *N*-benzyl-4-formyl-benzenesulfonamide in Step B. The title compound was obtained as a gray powder (59 mg, 25%). HPLC (Method C): R_t = 4.91. MS (ESI): mass calculated for $C_{21}H_{16}Cl_2N_4O_3S$, 474.0; m/z found, 475.3 $[M+H]^+$. 1H NMR (400 MHz, CD_3OD): δ 8.24-8.22 (m, 3H), 7.95 (d, J = 8.5 Hz, 2H), 7.86 (d, J = 9.3 Hz, 1H), 7.69 (d, J = 8.5 Hz, 1H), 7.37-7.32 (m, 2H), 7.16 (d, J = 2.0 Hz, 1H), 4.14 (s, 2H).
- 10

Example 51




- 15 2-[4-(Benzyl-methyl-sulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

A. *N*-Benzyl-4-formyl-*N*-methyl-benzenesulfonamide. This compound was prepared as described in Example 46, Step A, substituting *N*-methylbenzylamine (296 mg, 2.44 mmol) for benzylamine. The title compound was obtained as a white solid (675 mg, 96%).

- 20 B. 2-[4-(Benzyl-methyl-sulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide. This compound was prepared as described in Example 46 Step B, substituting *N*-benzyl-4-formyl-*N*-methyl-benzenesulfonamide (171 mg, 0.497 mmol) for *N*-benzyl-4-formyl-benzenesulfonamide. The reaction was run at 90 °C instead of 60 °C. The title compound was obtained as an off-white
- 25 powder (37 mg, 13%). HPLC (Method C): R_t = 4.84. MS (ESI): mass calculated for $C_{22}H_{20}N_4O_3S$, 420.1; m/z found, 421.1 $[M+H]^+$. 1H NMR (400 MHz, C_2D_6SO): δ 8.47 (d, J = 8.5 Hz, 2H), 8.23 (bs, 1H), 8.07 (d, J = 8.5 Hz, 3H), 7.85 (d, J = 8.5 Hz, 1H), 7.69 (d, J = 8.5 Hz, 1H), 7.39-7.32 (m, 5H), 4.22 (s, 2H), 2.61 (s, 3H).


Example 52



2-[4-(Tetrahydro-pyran-4-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

- 5 The title compound was prepared as described in Example 4 substituting tetrahydro-pyran-4-carbaldehyde for 4-chloro-benzaldehyde in Step A. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.27. HPLC (Method A): R_t = 6.27. MS (ESI+): mass calculated for C₂₀H₁₉N₃O₃, 349.1; m/z found, 350.1 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.17 (d, *J* = 8.4 Hz, 3H), 8.10 (d, *J* = 8.4 Hz, 2H), 7.82-7.80 (dd, *J* = 8.4, 1.3 Hz, 1H), 7.63 (br d, *J* = 8.1 Hz, 1H), 4.00-3.97 (m, 2H), 3.68-3.58 (m, 3H), 1.79-1.70 (m, 4H).
- 10


Example 53



2-[4-(Thiophene-2-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

- 15 The title compound was prepared as described in Example 4 substituting thiophene-2-carbaldehyde for 4-chloro-benzaldehyde in Step A. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.26. HPLC (Method A): R_t = 6.90. MS (ESI+): mass calculated for C₁₉H₁₃N₃O₂S, 347.0; m/z found, 348.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.17 (d, *J* = 8.4 Hz, 2H), 8.12 (br s, 1H), 7.92 (d, *J* = 8.4 Hz, 2H), 7.87-7.86 (dd, *J* = 5.0, 1.0 Hz, 1H), 7.75 (d, *J* = 8.3 Hz, 1H), 7.68-7.67 (dd, *J* = 3.8, 1.0 Hz, 1H), 7.58 (br s, 1H), 7.18-7.16 (dd, *J* = 4.9, 3.8 Hz, 1H).
- 20


Example 54



2-[4-(6-Chloro-benzo[1,3]dioxole-5-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

- 5 The title compound was prepared as described in Example 4 substituting 6-chloro-benzo[1,3]dioxole-5-carbaldehyde for 4-chloro-benzaldehyde in Step A. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.37. HPLC (Method A): R_t = 7.47. MS (ESI⁺): mass calculated for C₂₂H₁₄ClN₃O₄, 419.1; m/z found, 420.2, 422.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.15 (d, *J* = 8.5 Hz, 2H), 8.14 (br s, 1H), 7.85 (d, *J* = 8.6 Hz, 1H), 7.75 (d, *J* = 8.4 Hz, 1H), 7.59 (br s, 1H), 6.93 (s, 1H), 6.86 (s, 1H), 6.02 (s, 2H).
- 10


Example 55



2-[4-(2-Chloro-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

- 15 The title compound was prepared as described in Example 4 substituting 2-chloro-benzaldehyde for 4-chloro-benzaldehyde in Step A. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.31. HPLC (Method A): R_t = 7.44. MS (ESI⁺): mass calculated for C₂₁H₁₄ClN₃O₂, 375.1; m/z found, 376.3 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.16 (d, *J* = 8.4 Hz, 2H), 8.11 (br s, 1H), 7.85 (d, *J* = 8.6 Hz, 2H), 7.75 (br s, 1H), 7.59 (br s, 1H), 7.49-7.47 (m, 2H), 7.46-7.35 (m, 2H).
- 20

Example 56



2-[4-(2,4-Dichloro-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 4 substituting 2,4-

5 dichloro-benzaldehyde for 4-chloro-benzaldehyde in Step A. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.28. HPLC


(Method A): R_t = 7.91. MS (ESI⁺): mass calculated for C₂₁H₁₃Cl₂N₃O₂, 409.0;

m/z found, 410.1, 412.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.17 (d, *J* =

8.6 Hz, 2H), 8.12 (br s, 1H), 7.85 (d, *J* = 8.6 Hz, 2H), 7.76-7.74 (dd, *J* = 8.5, 1.5

10 Hz, 1H), 7.59 (br d, *J* = 8.3 Hz, 1H), 7.56 (d, *J* = 1.9 Hz, 1H), 7.45-7.43 (dd, *J* = 8.2, 1.9 Hz, 1H), 7.40 (d, *J* = 8.2 Hz, 1H).

Example 57



2-[4-(2-Methoxy-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

15 The title compound was prepared as described in Example 4 substituting 2-methoxy-benzaldehyde for 4-chloro-benzaldehyde in Step A. HPLC (Method

A): R_t = 7.16. MS (ESI⁺): mass calculated for C₂₂H₁₇N₃O₃, 371.1; m/z found,


372.3 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.09 (br s, 1H), 8.06 (d, *J* = 8.6

Hz, 2H), 7.75 (d, *J* = 8.6 Hz, 2H), 7.73-7.71 (dd, *J* = 8.5, 1.6 Hz, 1H), 7.54 (d, *J*

20 = 8.4 Hz, 1H), 7.45-7.42 (m, 1H), 7.27-7.26 (dd, *J* = 7.5, 1.7 Hz, 1H), 7.02 (d, *J*


= 8.3 Hz, 1H), 6.99-6.96 (m, 1H), 3.59 (s, 3H).

Example 58

2-[4-(2-Methyl-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide


The title compound was prepared as described in Example 4 substituting 2-methyl-benzaldehyde for 4-chloro-benzaldehyde in Step A. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.26. HPLC (Method A): R_t = 7.43. MS (ESI⁺): mass calculated for C₂₂H₁₇N₃O₂, 355.1; m/z found, 356.3 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.15 (d, *J* = 8.6 Hz, 2H), 8.14 (br s, 1H), 7.84 (d, *J* = 8.6 Hz, 2H), 7.76-7.74 (dd, *J* = 8.5, 1.3 Hz, 1H), 7.60 (br s, 1H), 7.39-7.36 (m, 1H), 7.29-7.22 (m, 3H), 2.23 (s, 3H).

Example 59

2-{4-[Hydroxy-(tetrahydro-pyran-4-yl)-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide


The title compound was prepared as described in Example 19 from 2-[4-(tetrahydro-pyran-4-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide (Example 52, 50 mg, 0.14 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 38 mg (76%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.06. HPLC (Method A): R_t = 5.76. MS (ESI⁺): mass calculated for C₂₀H₂₁N₃O₃, 351.1; m/z found, 352.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.08 (br s, 1H), 7.99 (d, *J* = 8.2 Hz, 2H), 7.72 (d, *J* = 8.3 Hz, 1H), 7.54 (br s, 1H), 7.43 (d, *J* = 8.3 Hz, 2H), 4.33 (d, *J* = 7.0 Hz, 1H), 3.89-3.86 (dd, *J* = 11.4, 3.8 Hz, 1H), 3.79-3.76 (dd, *J* = 11.3, 3.3 Hz, 1H), 3.31-3.26 (m, 2H), 1.83-1.74 (m, 2H), 1.40-1.25 (m, 2H), 1.15-1.12 (d, *J* = 12.6 Hz, 1H).

Example 60

2-[4-(Hydroxy-thiophen-2-yl-methyl)-phenyl]-1*H*-benzimidazole-5-carboxylic acid amide

- 5 The title compound was prepared as described in Example 19 from 2-[4-(thiophene-2-carbonyl)-phenyl]-1*H*-benzimidazole-5-carboxylic acid amide (Example 53, 19 mg, 0.04 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 11 mg (78%) of the title compound. TLC (silica, 1% methanol saturated with
- 10 ammonia/9% methanol/CH₂Cl₂): R_f = 0.17. HPLC (Method A): R_t = 6.48. MS (ESI⁺): mass calculated for C₁₉H₁₅N₃O₂S, 349.1; m/z found, 350.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.07 (br s, 1H), 8.01 (d, *J* = 8.3 Hz, 2H), 7.72 (br d, *J* = 7.9 Hz, 1H), 7.54 (d, *J* = 8.3 Hz, 3H), 7.23-7.22 (dd, *J* = 3.9, 2.4 Hz, 1H), 6.85-6.83 (m, 3H).


15 Example 61

2-[4-[(6-Chloro-benzo[1,3]dioxol-5-yl)-hydroxy-methyl]-phenyl]-1*H*-benzimidazole-5-carboxylic acid amide

- The title compound was prepared as described in Example 19 from 2-[4-(6-chloro-benzo[1,3]dioxole-5-carbonyl)-phenyl]-1*H*-benzimidazole-5-carboxylic acid amide (Example 54, 150 mg, 0.35 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 136 mg (91%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.21. HPLC (Method A):
- 20 R_t = 6.88. MS (ESI⁺): mass calculated for C₂₂H₁₆ClN₃O₄, 421.1; m/z found,
- 25

422.2, 424.2 $[M+H]^+$. 1H NMR (500 MHz, CD_3OD): δ 8.06 (br s, 1H), 7.96 (d, J = 8.4 Hz, 2H), 7.71 (dd, J = 8.4, 1.4 Hz, 1H), 7.53 (br s, 1H), 7.45 (d, J = 8.2 Hz, 2H), 6.97 (s, 1H), 6.75 (s, 1H), 6.06 (s, 1H), 5.88 (s, 1H), 5.85 (s, 1H).

Example 62




5

2-{4-[(2-Chloro-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 19 from 2-[4-(2-Chloro-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide (Example 55, 125 mg, 0.3 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2) afforded 114 mg (91%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2): R_f = 0.19. HPLC (Method A): R_t = 6.83. MS (ESI⁺): mass calculated for $C_{21}H_{16}ClN_3O_2$, 377.1; m/z found, 378.3, 380.2 $[M+H]^+$. 1H NMR (500 MHz, CD_3OD): δ 8.06 (br s, 1H), 7.95 (d, J = 8.2 Hz, 2H), 7.70 (d, J = 8.3 Hz, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.52 (br s, 1H), 7.45 (d, J = 8.2 Hz, 2H), 7.27-7.24 (m, 2H), 7.17-7.14 (m, 1H), 6.14 (s, 1H).

15

Example 63




20 2-{4-[(2,4-Dichloro-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 19 from 2-[4-(2,4-dichloro-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide (Example 56, 75 mg, 0.16 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/ CH_2Cl_2) afforded 61 mg

25

(81%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.27. HPLC (Method A): R_t = 7.24. MS (ESI⁺): mass calculated for C₂₁H₁₅Cl₂N₃O₂, 411.1; m/z found, 412.2, 414.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.07 (br s, 1H), 7.96 (d, *J* = 8.4 Hz, 2H), 7.71-7.69 (dd, *J* = 8.5, 1.6 Hz, 1H), 7.59 (d, *J* = 8.5 Hz, 1H), 7.53 (br d, *J* = 8.3 Hz, 1H), 7.44 (d, *J* = 8.3 Hz, 2H), 7.32 (d, *J* = 2.1 Hz, 1H), 7.29-7.27 (dd, 2 = 8.5, 2.1 Hz, 1H), 6.07 (s, 1H).

Example 64




2-[4-[Hydroxy-(2-methoxy-phenyl)-methyl]-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 19 from 2-[4-(2-methoxy-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide (Example 57, 120 mg, 0.3 mmol). Purification by chromatography (silica gel,

1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 101 mg (84%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.13. HPLC (Method A): R_t = 6.69. MS (ESI⁺): mass calculated for C₂₂H₁₉N₃O₃, 373.1; m/z found, 374.3 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.07 (br s, 1H), 7.93 (d, *J* = 8.3 Hz, 2H), 7.70 (br d, *J* = 8.2 Hz, 1H), 7.52 (br s, 1H), 7.45 (d, *J* = 8.3 Hz, 2H), 7.40-7.38 (dd, *J* = 7.6, 1.5 Hz, 1H), 7.16-7.13 (m, 1H), 6.88-6.84 (m, 2H), 6.10 (s, 1H), 3.70 (s, 3H).

Example 65




2-[4-(Hydroxy-*o*-tolyl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 19 from 2-[4-(2-methyl-benzoyl)-phenyl]-1*H*-benzimidazole-5-carboxylic acid amide.

- (Example 58, 100 mg, 0.28 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 78 mg (78%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.16. HPLC (Method A): R_t = 6.74. MS (ESI⁺): mass calculated for C₂₂H₁₉N₃O₂, 357.1; m/z found, 358.3 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.06 (br s, 1H), 7.95 (d, *J* = 8.3 Hz, 2H), 7.70 (d, *J* = 8.3 Hz, 1H), 7.52 (br s, 1H), 7.39 (d, *J* = 8.2 Hz, 2H), 7.35 (d, *J* = 7.4 Hz, 1H), 7.11-7.02 (m, 3H), 5.93 (s, 1H), 2.17 (s, 3H).


Example 66



2-[4-(6-Chloro-benzo[1,3]dioxol-5-ylmethyl)-phenyl]-1*H*-benzimidazole-5-carboxylic acid amide

- The title compound was prepared as described in Example 35 from 2-{4-[(6-chloro-benzo[1,3]dioxol-5-yl)-hydroxy-methyl]-phenyl}-1*H*-benzimidazole-5-carboxylic acid amide (Example 61, 53 mg, 0.12 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 34 mg (68%) of the title compound. TLC (silica, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂): R_f = 0.38. HPLC (Method A): R_t = 7.28. MS (ESI⁺): mass calculated for C₂₂H₁₆ClN₃O₃, 405.1, m/z found, 406.2, 408.3 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.18 (br s, 1H), 7.95 (d, *J* = 8.3 Hz, 2H), 7.93 (d, *J* = 1.6 Hz, 1H), 7.70 (d, *J* = 8.6 Hz, 1H), 7.42 (d, *J* = 8.4 Hz, 2H), 6.82 (s, 1H), 6.74 (s, 1H), 5.88 (s, 2H), 4.06 (s, 2H).


Example 67

2-[4-(2-Methoxy-benzyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

The title compound was prepared as described in Example 35 from 2-[4-


- 5 [hydroxy-(2-methoxy-phenyl)-methyl]-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide (Example 64, 30 mg, 0.08 mmol). Purification by chromatography (silica gel, 1% methanol saturated with ammonia/9% methanol/CH₂Cl₂) afforded 20 mg (71%) of the title compound. HPLC (Method A): *R*_t = 7.46. MS (ESI⁺): mass calculated for C₂₂H₁₉N₃O₂, 357.1, *m/z* found, 358.3 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.06 (br s, 1H), 7.88 (d, *J* = 8.4 Hz, 2H), 7.71-7.69 (dd, *J* = 8.5, 1.7 Hz, 1H), 7.51 (d, *J* = 8.4 Hz, 1H), 7.26 (d, *J* = 8.4 Hz, 2H), 7.12-7.08 (td, *J* = 8.2, 1.7 Hz, 1H), 7.05-7.03 (dd, *J* = 7.4, 1.6 Hz, 1H), 6.84 (d, *J* = 8.2 Hz, 1H), 6.79-6.76 (td, *J* = 7.4, 1.5 Hz, 1H), 3.91 (s, 2H), 3.69 (s, 3H).

Example 68



- 15 2-[4-(2-Methyl-benzyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide
The title compound was prepared as described in Example 35 from 2-[4-(hydroxy-*o*-tolyl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide (Example 65, 11 mg, 0.03 mmol). Product was isolated as a TFA salt (7 mg, 20 70%). HPLC (Method A): *R*_t = 7.93. MS (ESI⁺): mass calculated for C₂₂H₁₉N₃O, 341.1, *m/z* found, 342.3 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD): δ 8.06 (br s, 1H), 7.91 (d, *J* = 8.3 Hz, 2H), 7.71 (d, *J* = 8.2 Hz, 1H), 7.53 (br s, 1H), 7.20 (d, *J* = 8.4 Hz, 2H), 7.08-7.02 (m, 4H), 3.99 (s, 2H), 2.13 (s, 3H).

Example 69




2-[4-(2-Methyl-benzylsulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

- 5 A. 4-Formyl-*N*-(2-methyl-benzyl)-benzenesulfonamide. This compound was prepared as described in Example 46 substituting 2-methylbenzylamine (119 mg, 0.978 mmol) for benzylamine in Step A. The title compound was obtained as a white solid, 260 mg (92%).

- 10 B. 2-[4-(2-Methyl-benzylsulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide. This compound was prepared as described in Example 46 substituting 4-formyl-*N*-(2-methyl-benzyl)-benzenesulfonamide (172 mg, 0.662 mmol) for *N*-benzyl-4-formyl-benzenesulfonamide in Step B. The title compound was obtained as a beige solid, 81 mg (29%). HPLC (Method C): $R_t = 4.61$. MS (ESI): mass calculated for $C_{22}H_{20}N_4O_3S$, 420.1; m/z found, 421.1
- 15 $[M+H]^+$. 1H NMR (400 MHz, DMSO- d_6): δ 8.41 (d, $J = 8.4$ Hz, 2H), 8.11 (bm, 3H), 7.86 (d, $J = 8.1$ Hz, 1H), 7.69 (bs, 1H), 7.37 (bs, 1H), 7.23 (d, $J = 6.8$ Hz, 1H), 7.16 (m, 3H), 4.03 (s, 2H), 2.24 (s, 3H).

Example 70




- 20 2-[4-(3-Methyl-benzylsulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide
- A. 4-Formyl-*N*-(3-methyl-benzyl)-benzenesulfonamide. This compound was prepared as described in Example 46 substituting 3-methylbenzylamine (119 mg, 0.978 mmol) for benzylamine in Step A. The title compound was obtained
- 25 as a white solid, 250 mg (88%).
- B. 2-[4-(3-Methyl-benzylsulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide. This compound was prepared as described in Example 46

substituting 4-formyl-*N*-(3-methyl-benzyl)-benzenesulfonamide (172 mg, 0.662 mmol) for *N*-benzyl-4-formyl-benzenesulfonamide in Step B. The title compound was obtained as a beige solid, 72 mg (26%). HPLC (Method C): R_t = 4.63. MS (ESI): mass calculated for $C_{22}H_{20}N_4O_3S$, 420.1; m/z found, 421.1

- 5 $[M+H]^+$. 1H NMR (400 MHz, DMSO- d_6): δ 8.36 (d, J = 8.5 Hz, 2H), 8.04 (bs, 1H), 7.96 (d, J = 8.5 Hz, 2H), 7.83 (dd, J = 8.5, 1.4 Hz, 1H), 7.67 (d, J = 8.5 Hz, 1H), 7.33 (bs, 1H), 7.16 (t, J = 7.7 Hz, 1H), 7.03 (bm, 3H), 4.03 (s, 2H), 2.21 (s, 3H).

Example 71




2-[4-(1,3-Dihydro-isoindole-2-sulfonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide

- A. 4-(1,3-Dihydro-isoindole-2-sulfonyl)-benzaldehyde. This compound was prepared as described in Example 46 substituting isoindoline (117 mg, 0.978 mmol) for benzylamine in Step A. The title compound was obtained as a white solid, 253 mg (90%).

- B. 2-[4-(1,3-Dihydro-isoindole-2-sulfonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide. This compound was prepared as described in Example 46 substituting 4-(1,3-dihydro-isoindole-2-sulfonyl)-benzaldehyde (190 mg, 0.662 mmol) for *N*-benzyl-4-formyl-benzenesulfonamide in Step B. The title compound was obtained as a yellow powder, 122 mg (44%). HPLC (Method C): R_t = 4.69. MS (ESI): mass calculated for $C_{22}H_{18}N_4O_3S$, 418.5; m/z found, 419.1 $[M+H]^+$. 1H NMR (400 MHz, DMSO- d_6): δ 8.41 (d, J = 8.5 Hz, 2H), 8.07 (d, J = 8.5 Hz, 1H), 8.03 (bs, 1H), 7.81 (bd, J = 8.1 Hz, 1H), 7.65 (bs, 1H), 7.33 (bs, 1H), 7.25 (m, 5H), 4.65 (s, 4H).

Example 72




2-[4-(2,3-Dihydro-indole-1-sulfonyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide

A. 4-(2,3-Dihydro-indole-2-sulfonyl)-benzaldehyde. This compound was prepared as described in Example 46 substituting indoline (117 mg, 0.978 mmol) for benzylamine in Step A. The title compound was obtained as a tan solid, 250 mg (89%).

B. 2-[4-(2,3-Dihydro-indole-2-sulfonyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide. This compound was prepared as described in Example 46 substituting 4-(2,3-dihydro-indole-2-sulfonyl)-benzaldehyde (202 mg, 0.703 mmol) for *N*-benzyl-4-formyl-benzenesulfonamide in Step B. The title compound was obtained as a beige powder, 130 mg (44%). HPLC (Method C): R_t = 4.80. MS (ESI): mass calculated for $C_{22}H_{18}N_4O_3S$, 418.5; m/z found, 419.1 $[M+H]^+$. 1H NMR (400 MHz, DMSO- d_6): δ 8.36 (d, J = 8.2 Hz, 2H), 8.22 (s, 1H), 8.04 (m, 3H), 7.84 (d, J = 8.4 Hz, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.36 (s, 1H), 7.20 (m, 2H), 7.01 (m, 1H), 4.01 (t, J = 8.2 Hz, 2H), 2.94 (t, J = 8.1 Hz, 2H).

Example 73




(±)-2-[4-(1-Phenyl-ethylsulfamoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide

A. (±) 4-Formyl-N-(1-phenyl-ethyl)-benzenesulfonamide. This compound was prepared as described in Example 46 substituting (±)- α -methylbenzylamine (119 mg, 0.978 mmol) for benzylamine in Step A. The title compound was obtained as a white solid, 223 mg (79%).

B. (±)-2-[4-(1-Phenyl-ethylsulfamoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide. This compound was prepared as described in Example 46 substituting (±) 4-Formyl-N-(1-phenyl-ethyl)-benzenesulfonamide (198 mg, 0.686 mmol) for *N*-benzyl-4-formyl-benzenesulfonamide in Step B. The title compound was obtained as a beige powder, 96 mg (33%). HPLC (Method C): R_t = 4.49. MS (ESI): mass calculated for $C_{22}H_{20}N_4O_3S$, 420.5; m/z found, 421.1

$[M+H]^+$. 1H NMR (400 MHz, DMSO- d_6): δ 8.39 (d, J = 8.2 Hz, 1H), 8.28 (d, J = 8.5 Hz, 2H), 8.15 (bs, 1H), 7.86 (d, J = 8.5 Hz, 3H), 7.75 (bs, 1H), 7.40 (bs, 1H), 7.19 (m, 5H), 4.46 (q, J = 7.1 Hz, 1H), 1.28 (d, J = 6.9 Hz, 3H).

Example 74



(±)-2-[4-(1,2,3,4-Tetrahydro-naphthalen-1-ylsulfamoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide

A. (±) 4-Formyl-N-(1,2,3,4-tetrahydro-naphthalen-1-yl)-benzenesulfonamide.


This compound was prepared as described in Example 46 substituting (±)-1,2,3,4-tetrahydro-1-naphthylamine (144 mg, 0.978 mmol) for benzylamine in Step A. The title compound was obtained as a white solid, 210 mg (68%).

B. (±)-2-[4-(1,2,3,4-Tetrahydro-naphthalen-1-ylsulfamoyl)-phenyl]-1H-

benzoimidazole-5-carboxylic acid amide. This compound was prepared as described in Example 46 substituting (±) 4-formyl-N-(1,2,3,4-tetrahydro-

naphthalen-1-yl)-benzenesulfonamide (209 mg, 0.662 mmol) for N-benzyl-4-formyl-benzenesulfonamide in Step B. The title compound was obtained as a beige powder, 94 mg (32%). HPLC (Method C): R_t = 4.80. MS (ESI): mass calculated for $C_{24}H_{22}N_4O_3S$, 446.5; m/z found, 447.1 $[M+H]^+$. 1H NMR (400 MHz, DMSO- d_6): δ 8.43 (d, J = 8.5 Hz, 2H), 8.24 (bm, 2H), 8.08 (d, J = 8.5 Hz, 2H), 8.05 (m, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.72 (bm, 1H), 7.34 (bs, 1H), 7.09 (m, 4H), 4.51 (bd, J = 3.4 Hz, 1H), 2.65 (bm, 2H), 1.79 (bm, 1H), 1.61 (bm, 3H).

Example 75




2-{4-[(Thiophen-2-ylmethyl)-sulfamoyl]-phenyl}-1H-benzoimidazole-5-carboxylic acid amide

A. 4-Formyl-*N*-thiophen-2-ylmethyl-benzenesulfonamide. This compound was prepared as described in Example 46 substituting (2-aminomethyl)thiophene (111 mg, 0.978 mmol) for benzylamine in Step A. The title compound was obtained as a white solid, 201 mg (73%).

- 5 B. 2-{4-[(Thiophen-2-ylmethyl)-sulfamoyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide. This compound was prepared as described in Example 46 substituting 4-formyl-*N*-thiophen-2-ylmethyl-benzenesulfonamide (186 mg, 0.662 mmol) for *N*-benzyl-4-formyl-benzenesulfonamide in Step B. The title compound was obtained as a beige powder, 114 mg (42%). HPLC (Method C):
- 10 $R_t = 4.40$. MS (ESI): mass calculated for $C_{19}H_{16}N_4O_3S_2$, 412.5; m/z found, 413.0 $[M+H]^+$. 1H NMR (400 MHz, DMSO- d_6): δ 8.39 (d, $J = 8.5$ Hz, 2H), 8.30 (bs, 1H), 8.15 (bs, 1H), 7.99 (d, $J = 8.5$ Hz, 2H), 7.85 (d, $J = 8.4$ Hz, 1H), 7.67 (bm, 1H), 7.40 (dd, $J = 5.0, 1.3$ Hz, 1H), 7.36 (bs, 1H), 6.94 (d, $J = 2.4$ Hz, 1H), 6.91 (dd, $J = 5.0, 3.5$ Hz, 1H), 4.29 (s, 2H).

15 Example 76




2-{4-[(Furan-2-ylmethyl)-sulfamoyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide

- A. 4-Formyl-*N*-furan-2-ylmethyl-benzenesulfonamide. This compound was prepared as described in Example 46 substituting furfurylamine (95 mg, 0.978 mmol) for benzylamine in Step A. The title compound was obtained as a white solid, 203 mg (78%).
- 20 B. 2-{4-[(Furan-2-ylmethyl)-sulfamoyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide. This compound was prepared as described in Example 46 substituting 4-formyl-*N*-furan-2-ylmethyl-benzenesulfonamide (176 mg, 0.662 mmol) for *N*-benzyl-4-formyl-benzenesulfonamide in Step B. The title compound was obtained as a beige powder, 118 mg (45%). HPLC (Method C):
- 25 $R_t = 4.24$. MS (ESI): mass calculated for $C_{19}H_{16}N_4O_4S$, 396.4; m/z found, 397.1 $[M+H]^+$. 1H NMR (400 MHz, DMSO- d_6): δ 8.36 (d, $J = 8.5$ Hz, 2H), 8.22 (bs, 1H), 8.05 (bs, 1H), 7.94 (d, $J = 8.5$ Hz, 2H), 7.84 (d, $J = 8.3$ Hz, 1H), 7.68 (bm,
- 30 1H), 7.40 (dd, $J = 5.0, 1.3$ Hz, 1H), 7.36 (bs, 1H), 6.94 (d, $J = 2.4$ Hz, 1H), 6.91 (dd, $J = 5.0, 3.5$ Hz, 1H), 4.29 (s, 2H).

1H), 7.49 (d, $J = 0.91$ Hz, 1H), 7.35 (bm, 1H), 6.30 (dd, $J = 3.0, 1.9$ Hz, 1H), 6.20 (d, $J = 3.0$ Hz, 1H), 4.10 (s, 2H).

Example 77




- 5 2-{4-[(Pyridin-4-ylmethyl)-sulfamoyl]-phenyl}-1H-benzoimidazole-5-carboxylic acid amide

A. 4-Formyl-N-pyridin-4-ylmethyl-benzenesulfonamide. This compound was prepared as described in Example 46 substituting (4-aminomethyl)pyridine (106 mg, 0.978 mmol) for benzylamine in Step A. The title compound was
10 obtained as a yellow solid, 219 mg (81%).

B. 2-{4-[(Pyridin-4-ylmethyl)-sulfamoyl]-phenyl}-1H-benzoimidazole-5-carboxylic acid amide. This compound was prepared as described in Example 46 substituting 4-formyl-N-pyridin-4-ylmethyl-benzenesulfonamide (190 mg, 0.688 mmol) for N-benzyl-4-formyl-benzenesulfonamide in Step B. The title
15 compound was obtained as a beige powder, 88 mg (31%). HPLC (Method C): $R_t = 3.57$. MS (ESI): mass calculated for $C_{20}H_{17}N_5O_3S$, 407.5; m/z found, 408.1 $[M+H]^+$. 1H NMR (400 MHz, DMSO- d_6): δ 8.48 (m, 3H), 8.38 (bd, $J = 6.2$ Hz, 2H), 8.32 (bs, 1H), 8.05 (bm, 4H), 7.86 (m, 2H), 7.63 (bm, 1H), 7.35 (bm, 1H), 7.30 (d, $J = 5.7$ Hz, 2H), 4.14 (bd, $J = 5.6$ Hz, 2H).

20 Example 78



2-[4-((S)-Indan-1-ylsulfamoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide

A. 4-Formyl-N-indan-(S)-1-yl-benzenesulfonamide. This compound was prepared as described in Example 46 substituting S-(+)-1-aminoindane (130 mg, 0.978 mmol) for benzylamine in Step A. The title compound was obtained
25 as a white solid, 242 mg (82%).

B. 2-[4-(S)-Indan-1-ylsulfamoyl]-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide. This compound was prepared as described in Example 46 substituting

4-formyl-*N*-indan-(*S*)-1-yl-benzenesulfonamide (199 mg, 0.662 mmol) for *N*-benzyl-4-formyl-benzenesulfonamide in Step B. The title compound was

- 5 obtained as a beige powder, 74 mg (26%). HPLC (Method C): R_t = 4.68. MS (ESI): mass calculated for $C_{23}H_{20}N_4O_3S$, 432.5; m/z found, 433.1 $[M+H]^+$. 1H NMR (400 MHz, DMSO- d_6): δ 8.43 (d, J = 8.3 Hz, 2H), 8.23 (bm, 2H), 8.09 (d, J = 8.3 Hz, 2H), 8.06 (m, 1H), 7.84 (d, J = 8.3 Hz, 1H), 7.69 (m, 1H), 7.35 (bs, 1H), 7.16 (m, 4H), 4.79 (bm, 1H), 2.82 (m, 1H), 2.69 (m, 1H), 2.10 (m, 1H),
10 1.66 (m, 1H).

Example 79

Determination of compound inhibition of human Cds1 activity

- For the determination of human Cds1 activity in the presence of Cds1 inhibitory compounds, such compounds were incubated in an aqueous mixture
15 at pH 7.4 containing 50 mM HEPES, 100 mM NaCl, 10 mM $MgCl_2$, 5 nM recombinant human Cds1, 10 μ M synthetic peptide substrate SGLYRSPSPENLNRP having an N-terminal biotin, 1 μ M adenosine triphosphate, 50 μ Ci/mL of $[\gamma\text{-}^{33}P]$ adenosine triphosphate, and a protease inhibitor mixture. The reaction mixtures were incubated at 37 °C for 3 h. The
20 peptide substrate was captured from the reaction mixture by incubating the reaction mixture with streptavidin conjugated to agarose beads and 50 mM adenosine triphosphate. The agarose beads were washed repeatedly with a 0.1% solution of Tween®-20 in phosphate-buffered saline, pH 7.4. Enzyme activity at different Cds1 inhibitory compound concentrations was determined
25 by measuring the amount of radioactive phosphate bound to the substrate peptide by scintillation counting. Results are expressed as IC_{50} in Table 1 below.

Table 1: Cds1 Inhibition

Example	IC_{50} (nM)	Example	IC_{50} (nM)
<u>1</u>	55	<u>40</u>	171
<u>2</u>	66	<u>41</u>	3

<u>3</u>	64	<u>42</u>	5
<u>4</u>	43	<u>43</u>	264
<u>5</u>	33	<u>44</u>	113
<u>6</u>	43	<u>45</u>	38
<u>7</u>	7	<u>46</u>	56
<u>8</u>	11	<u>47</u>	112
<u>9</u>	34	<u>48</u>	150
<u>10</u>	7	<u>49</u>	66
<u>11</u>	17	<u>50</u>	99
<u>12</u>	13	<u>51</u>	290
<u>13</u>	36	<u>52</u>	182
<u>14</u>	39	<u>53</u>	77
<u>15</u>	38	<u>54</u>	54
<u>16</u>	240	<u>55</u>	49
<u>17</u>	32	<u>56</u>	18
<u>18</u>	192	<u>57</u>	170
<u>19</u>	29	<u>58</u>	40
<u>20</u>	9	<u>59</u>	1100
<u>21</u>	16	<u>60</u>	42
<u>22</u>	33	<u>61</u>	40
<u>23</u>	5	<u>62</u>	80
<u>24</u>	4	<u>63</u>	14
<u>25</u>	71	<u>64</u>	272
<u>26</u>	8	<u>65</u>	114
<u>27</u>	7	<u>66</u>	41
<u>28</u>	13	<u>67</u>	45
<u>29</u>	23	<u>68</u>	42
<u>30</u>	47	<u>69</u>	42
<u>31</u>	9	<u>70</u>	50
<u>32</u>	164	<u>71</u>	9
<u>33</u>	98	<u>72</u>	18
<u>34</u>	42	<u>73</u>	181

<u>35</u>	4	<u>74</u>	16
<u>36</u>	5	<u>75</u>	19
<u>37</u>	5	<u>76</u>	37
<u>38</u>	12	<u>77</u>	134
<u>39</u>	26	<u>78</u>	10

Example 80

Determination of the effect of Cds1 inhibitory compounds on radiation-induced apoptosis in isolated primary cells

5 Spleen cells were isolated from C57/BL6 mice as follows: spleens were disrupted by grinding between two frosted glass slides, and cells were passed through a cell strainer. Erythrocytes were lysed by incubation in ammonium chloride solution followed by careful washing of cells in isotonic medium. The spleen cells were plated in 60 mm petri dishes at 5×10^6 cells/mL in RPMI
10 medium containing 10% fetal calf serum and Cds1 inhibitor. One hour after plating of cells with compound, the cells were dosed with 0.5–1 Gy from a ^{137}Cs γ -radiation source. Determination of apoptotic cells by Annexin V staining was performed using the Annexin V-FITC Apoptosis Detection Kit™ (Cat# PF032 Oncogene Research Products) according to the manufacturer's
15 instructions. Briefly, 6–24 h after irradiation, the cells were washed with buffered isotonic salt solution and suspended at 1×10^6 cells/mL in binding buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 2.5 mM CaCl_2 , 1 mM MgCl_2 , 4% bovine serum albumin) containing 80 ng/mL Annexin V labelled with FITC and 0.4 $\mu\text{g/mL}$ anti-B220 antibody labelled with allophycocyanin. The cells were
20 then pelleted and resuspended in binding buffer containing 0.6 $\mu\text{g/mL}$ propidium iodide. The stained cells were analyzed on a FACS machine (Fluorescence Activated Cell Sorter™, Becton Dickinson). The fraction of viable, non-apoptotic cells was determined by quantifying the number of cells that did not stain with propidium iodide or Annexin V versus the total number of
25 cells. Fractions of non-apoptotic B-cells or total cells were determined separately based on staining with the B220 antibody mentioned above.

Example 81

Determination of effect of Cds1 inhibitors on radiation-induced caspase activity in human CD4⁺ T-cells

Human CD4⁺ T-cells were isolated from the blood of healthy donors as follows. Whole heparinized blood was layered over Ficoll-Paque (Amersham Pharmacia Biotech, Uppsala, Sweden) and centrifuged 20 min at 560g. Mononuclear cells were harvested and subjected to positive selection with anti-human CD4-coated MACS MicroBeads (Miltenyi, Auburn, CA). Purified CD4⁺ T-cells were transferred to growth medium (RPMI with 10% fetal calf serum, 50%IU/mL penicillin and 50 µg/mL streptomycin). The cells were dispensed to wells of 96-well tissue culture plates at 200,000 cells/well. Either a Cds1 inhibitory compound in DMSO or the same volume of vehicle was added to each well. The reaction mixtures were incubated at 37 °C for 1 h, exposed to 10 Gy of γ-radiation, and then incubated for 24 h. The CD4⁺ T-cells were harvested by centrifugation and lysed to release caspase-3. Caspase-3 and caspase-7 specific fluorogenic peptide substrate Acetyl-Asp-Glu-Val-Asp-(7-amino-4-methyl-coumarin) was added to each sample (final concentration = 100 µM). Three hours after the addition of peptide, the caspase activity of each sample was determined fluorometrically using a Millipore Cytofluor fluorescent plate reader (λ_{ex} = 360 nm, λ_{em} = 460 nm).

Example 82

Determination of the effect of Cds1 inhibitory compounds on radiation-induced apoptosis in human CD4⁺ T-cells

Human CD4⁺ T-cells were isolated from the blood of healthy donors and cultured as described in Example 54. The cells were dispensed to wells of 96-well tissue culture plates at 200,000 cells/well. Either a Cds1 inhibitory compound in DMSO or the same volume of vehicle was added to each well. The reaction mixtures were incubated at 37 °C for 1 h, exposed to 10 Gy of γ-radiation, and then incubated for 24 h. Determination of apoptotic cells by Annexin V staining was performed as described in Example 53.

Example 83

Determination of the effect of Cds1 inhibitory compounds on radiation-induced apoptosis in splenocytes *in vivo*

Female C57/BL mice, 6–8 weeks of age, are dosed by oral gavage or by injection with Cds1 inhibitory compound before and at regular intervals after radiation exposure. One to three hours after first compound dose, the animals are irradiated with γ -rays administered to the whole animal at a dose between 0.5 and 4 Gy. At times between 4 and 24 h after irradiation, the animals are sacrificed, and the tissues of interest are excised. Cell apoptosis is quantified using Annexin V staining as described in Example 53. Apoptosis can be studied in a variety of tissues. In some cases other methods for quantification of apoptosis than the method described in Example 53 may be more appropriate. Thus, apoptosis can also be determined by detection of DNA degradation by TUNEL staining, as described by Darzynkiewicz and Bedner (In *Analysis of Apoptotic Cells by Flow and Laser Scanning Cytometry*; Reed, J.C., Ed.; Methods of Enzymology, Vol. 322; Academic Press: San Diego, 2000; 18–39). Briefly, cells or tissues are fixed with formaldehyde and permeabilized with ethanol, and DNA ends are then labelled by attaching nucleotide derivatives such as BrdUTP using the enzyme terminal deoxynucleotidyl transferase. DNA ends can then be detected by incubating the cells or tissues with fluorescently-labelled antibodies reactive with BrdU. Quantification can be done by laser scanning cytometry, by visual microscopical examination or by FACS.

25 F. Other Embodiments

The features and advantages of the invention are apparent to one of ordinary skill in the art. Based on this disclosure, including the summary, detailed description, background, examples, and claims, one of ordinary skill in the art will be able to make modifications and adaptations to various conditions and usages. These other embodiments are also within the scope of the invention.